{
  "source": "nih",
  "scraped_at": "2025-11-13T05:47:30.296753+00:00",
  "institutions": [
    {
      "institution_name": "STANFORD UNIVERSITY",
      "institution_type": "SCHOOLS OF MEDICINE",
      "street": null,
      "city": "STANFORD",
      "state": "CA",
      "zipcode": "943052004",
      "country": "UNITED STATES",
      "institution_phone": null,
      "departments": [
        {
          "department_name": "INTERNAL MEDICINE/MEDICINE",
          "department_email": null,
          "department_phone": null,
          "people": [
            {
              "person_name": "Sanjiv M Narayan",
              "person_email": "nih_1858208@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 1858208)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            }
          ]
        },
        {
          "department_name": "EMERGENCY MEDICINE",
          "department_email": null,
          "department_phone": null,
          "people": [
            {
              "person_name": "Brian Travis Rice",
              "person_email": "nih_15924210@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 15924210)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            }
          ]
        },
        {
          "department_name": "Unknown Department",
          "department_email": null,
          "department_phone": null,
          "people": [
            {
              "person_name": "Christopher  Re",
              "person_email": "nih_14472306@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 14472306)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            }
          ]
        },
        {
          "department_name": "BIOSTATISTICS & OTHER MATH SCI",
          "department_email": null,
          "department_phone": null,
          "people": [
            {
              "person_name": "Ron  Dror",
              "person_email": "nih_12509787@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 12509787)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            }
          ]
        },
        {
          "department_name": "CHEMISTRY",
          "department_email": null,
          "department_phone": null,
          "people": [
            {
              "person_name": "Thomas Edward Markland",
              "person_email": "nih_16325837@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 16325837)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            }
          ]
        }
      ]
    },
    {
      "institution_name": "DUKE UNIVERSITY",
      "institution_type": "BIOMED ENGR/COL ENGR/ENGR STA",
      "street": null,
      "city": "DURHAM",
      "state": "NC",
      "zipcode": "277054673",
      "country": "UNITED STATES",
      "institution_phone": null,
      "departments": [
        {
          "department_name": "BIOMEDICAL ENGINEERING",
          "department_email": null,
          "department_phone": null,
          "people": [
            {
              "person_name": "Daniel  Reker",
              "person_email": "nih_77918177@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 77918177)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            }
          ]
        }
      ]
    },
    {
      "institution_name": "NORTHWESTERN UNIVERSITY AT CHICAGO",
      "institution_type": "SCHOOLS OF MEDICINE",
      "street": null,
      "city": "CHICAGO",
      "state": "IL",
      "zipcode": "606114579",
      "country": "UNITED STATES",
      "institution_phone": null,
      "departments": [
        {
          "department_name": "NEUROLOGY",
          "department_email": null,
          "department_phone": null,
          "people": [
            {
              "person_name": "Joshua I Glaser",
              "person_email": "nih_12329894@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 12329894)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            }
          ]
        },
        {
          "department_name": "INTERNAL MEDICINE/MEDICINE",
          "department_email": null,
          "department_phone": null,
          "people": [
            {
              "person_name": "Catherine A. Gao",
              "person_email": "nih_16609793@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 16609793)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            }
          ]
        }
      ]
    },
    {
      "institution_name": "JACKSON LABORATORY",
      "institution_type": "Research Institutes",
      "street": null,
      "city": "BAR HARBOR",
      "state": "ME",
      "zipcode": "046091523",
      "country": "UNITED STATES",
      "institution_phone": null,
      "departments": [
        {
          "department_name": "Unknown Department",
          "department_email": null,
          "department_phone": null,
          "people": [
            {
              "person_name": "John Matthew Mahoney",
              "person_email": "nih_10947803@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 10947803)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            },
            {
              "person_name": "VIVEK  KUMAR",
              "person_email": "nih_2650198@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 2650198)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            },
            {
              "person_name": "Ann Kathryn Kennedy",
              "person_email": "nih_14123991@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 14123991)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            }
          ]
        }
      ]
    },
    {
      "institution_name": "BRIGHAM AND WOMEN'S HOSPITAL",
      "institution_type": "Independent Hospitals",
      "street": null,
      "city": "BOSTON",
      "state": "MA",
      "zipcode": "021156110",
      "country": "UNITED STATES",
      "institution_phone": null,
      "departments": [
        {
          "department_name": "Unknown Department",
          "department_email": null,
          "department_phone": null,
          "people": [
            {
              "person_name": "Travis Eli Gibson",
              "person_email": "nih_12435280@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 12435280)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            },
            {
              "person_name": "Vesela  Kovacheva",
              "person_email": "nih_15711428@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 15711428)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            }
          ]
        }
      ]
    },
    {
      "institution_name": "UNIVERSITY OF TEXAS HLTH SCIENCE CENTER",
      "institution_type": "SCHOOLS OF MEDICINE",
      "street": null,
      "city": "SAN ANTONIO",
      "state": "TX",
      "zipcode": "782293901",
      "country": "UNITED STATES",
      "institution_phone": null,
      "departments": [
        {
          "department_name": "RADIATION-DIAGNOSTIC/ONCOLOGY",
          "department_email": null,
          "department_phone": null,
          "people": [
            {
              "person_name": "Mohamad  Habes",
              "person_email": "nih_14571299@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 14571299)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            }
          ]
        }
      ]
    },
    {
      "institution_name": "UNIVERSITY OF WASHINGTON",
      "institution_type": "SCHOOLS OF ARTS AND SCIENCES",
      "street": null,
      "city": "SEATTLE",
      "state": "WA",
      "zipcode": "981959472",
      "country": "UNITED STATES",
      "institution_phone": null,
      "departments": [
        {
          "department_name": "BIOSTATISTICS & OTHER MATH SCI",
          "department_email": null,
          "department_phone": null,
          "people": [
            {
              "person_name": "Zaid  Harchaoui",
              "person_email": "nih_16345702@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 16345702)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            },
            {
              "person_name": "Azadeh  Yazdan Shahmorad",
              "person_email": "nih_14086113@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 14086113)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            }
          ]
        }
      ]
    },
    {
      "institution_name": "HARVARD MEDICAL SCHOOL",
      "institution_type": "SCHOOLS OF MEDICINE",
      "street": null,
      "city": "BOSTON",
      "state": "MA",
      "zipcode": "021201616",
      "country": "UNITED STATES",
      "institution_phone": null,
      "departments": [
        {
          "department_name": "MISCELLANEOUS",
          "department_email": null,
          "department_phone": null,
          "people": [
            {
              "person_name": "Kun-Hsing  Yu",
              "person_email": "nih_14074702@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 14074702)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            }
          ]
        },
        {
          "department_name": "INTERNAL MEDICINE/MEDICINE",
          "department_email": null,
          "department_phone": null,
          "people": [
            {
              "person_name": "Zeshan M Hussain",
              "person_email": "nih_14982777@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 14982777)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            }
          ]
        }
      ]
    },
    {
      "institution_name": "VANDERBILT UNIVERSITY",
      "institution_type": "SCHOOLS OF ARTS AND SCIENCES",
      "street": null,
      "city": "Nashville",
      "state": "TN",
      "zipcode": "372032408",
      "country": "UNITED STATES",
      "institution_phone": null,
      "departments": [
        {
          "department_name": "CHEMISTRY",
          "department_email": null,
          "department_phone": null,
          "people": [
            {
              "person_name": "Allison Sara Walker",
              "person_email": "nih_11587919@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 11587919)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            },
            {
              "person_name": "James E Crowe",
              "person_email": "nih_6465196@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 6465196)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            },
            {
              "person_name": "Jens  Meiler",
              "person_email": "nih_8585373@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 8585373)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            },
            {
              "person_name": "Torben  Schiffner",
              "person_email": "nih_14479879@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 14479879)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            }
          ]
        }
      ]
    },
    {
      "institution_name": "CARNEGIE-MELLON UNIVERSITY",
      "institution_type": "SCHOOLS OF ARTS AND SCIENCES",
      "street": null,
      "city": "PITTSBURGH",
      "state": "PA",
      "zipcode": "152133815",
      "country": "UNITED STATES",
      "institution_phone": null,
      "departments": [
        {
          "department_name": "BIOSTATISTICS & OTHER MATH SCI",
          "department_email": null,
          "department_phone": null,
          "people": [
            {
              "person_name": "JIAN  MA",
              "person_email": "nih_10363722@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 10363722)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            },
            {
              "person_name": "Tamar  Krishnamurti",
              "person_email": "nih_12470438@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 12470438)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            },
            {
              "person_name": "Bryan  Wilder",
              "person_email": "nih_78297124@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 78297124)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            }
          ]
        }
      ]
    },
    {
      "institution_name": "NEW YORK UNIVERSITY",
      "institution_type": "SCHOOLS OF PUBLIC HEALTH",
      "street": null,
      "city": "NEW YORK",
      "state": "NY",
      "zipcode": "100122300",
      "country": "UNITED STATES",
      "institution_phone": null,
      "departments": [
        {
          "department_name": "BIOSTATISTICS & OTHER MATH SCI",
          "department_email": null,
          "department_phone": null,
          "people": [
            {
              "person_name": "Shu  Xu",
              "person_email": "nih_12042562@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 12042562)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            },
            {
              "person_name": "Hai  Shu",
              "person_email": "nih_16250460@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 16250460)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            }
          ]
        }
      ]
    },
    {
      "institution_name": "JOHNS HOPKINS UNIVERSITY",
      "institution_type": "BIOMED ENGR/COL ENGR/ENGR STA",
      "street": null,
      "city": "BALTIMORE",
      "state": "MD",
      "zipcode": "212182680",
      "country": "UNITED STATES",
      "institution_phone": null,
      "departments": [
        {
          "department_name": "BIOMEDICAL ENGINEERING",
          "department_email": null,
          "department_phone": null,
          "people": [
            {
              "person_name": "JEREMIAS  SULAM",
              "person_email": "nih_15861391@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 15861391)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            }
          ]
        }
      ]
    },
    {
      "institution_name": "UNIVERSITY OF CALIFORNIA, SAN DIEGO",
      "institution_type": "SCHOOLS OF ARTS AND SCIENCES",
      "street": null,
      "city": "LA JOLLA",
      "state": "CA",
      "zipcode": "920930621",
      "country": "UNITED STATES",
      "institution_phone": null,
      "departments": [
        {
          "department_name": "ENGINEERING (ALL TYPES)",
          "department_email": null,
          "department_phone": null,
          "people": [
            {
              "person_name": "Siavash  Mir arabbaygi",
              "person_email": "nih_14342570@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 14342570)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            }
          ]
        }
      ]
    },
    {
      "institution_name": "NORTHEASTERN UNIVERSITY",
      "institution_type": "SCH ALLIED HEALTH PROFESSIONS",
      "street": null,
      "city": "BOSTON",
      "state": "MA",
      "zipcode": "021155005",
      "country": "UNITED STATES",
      "institution_phone": null,
      "departments": [
        {
          "department_name": "PSYCHOLOGY",
          "department_email": null,
          "department_phone": null,
          "people": [
            {
              "person_name": "Joshua  Curtiss",
              "person_email": "nih_78378444@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 78378444)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            }
          ]
        },
        {
          "department_name": "CHEMISTRY",
          "department_email": null,
          "department_phone": null,
          "people": [
            {
              "person_name": "Predrag  Radivojac",
              "person_email": "nih_8702983@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 8702983)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            }
          ]
        }
      ]
    },
    {
      "institution_name": "COLUMBIA UNIVERSITY HEALTH SCIENCES",
      "institution_type": "SCHOOLS OF MEDICINE",
      "street": null,
      "city": "NEW YORK",
      "state": "NY",
      "zipcode": "100323725",
      "country": "UNITED STATES",
      "institution_phone": null,
      "departments": [
        {
          "department_name": "BIOCHEMISTRY",
          "department_email": null,
          "department_phone": null,
          "people": [
            {
              "person_name": "Mohammed Nazar AlQuraishi",
              "person_email": "nih_12001814@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 12001814)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            }
          ]
        }
      ]
    },
    {
      "institution_name": "CEDARS-SINAI MEDICAL CENTER",
      "institution_type": "Independent Hospitals",
      "street": null,
      "city": "LOS ANGELES",
      "state": "CA",
      "zipcode": "900481804",
      "country": "UNITED STATES",
      "institution_phone": null,
      "departments": [
        {
          "department_name": "Unknown Department",
          "department_email": null,
          "department_phone": null,
          "people": [
            {
              "person_name": "Jason H. Moore",
              "person_email": "nih_6356426@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 6356426)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            },
            {
              "person_name": "Xiuzhen  Huang",
              "person_email": "nih_9624002@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 9624002)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            },
            {
              "person_name": "Xiaoqian  Jiang",
              "person_email": "nih_10960996@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 10960996)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            },
            {
              "person_name": "Karl  Walker",
              "person_email": "nih_12609329@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 12609329)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            }
          ]
        }
      ]
    },
    {
      "institution_name": "FLORIDA INTERNATIONAL UNIVERSITY",
      "institution_type": "BIOMED ENGR/COL ENGR/ENGR STA",
      "street": null,
      "city": "MIAMI",
      "state": "FL",
      "zipcode": "331992516",
      "country": "UNITED STATES",
      "institution_phone": null,
      "departments": [
        {
          "department_name": "BIOSTATISTICS & OTHER MATH SCI",
          "department_email": null,
          "department_phone": null,
          "people": [
            {
              "person_name": "Fahad  Saeed",
              "person_email": "nih_11340341@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 11340341)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            }
          ]
        }
      ]
    },
    {
      "institution_name": "COLLABORATIONS PHARMACEUTICALS, INC.",
      "institution_type": "Domestic For-Profits",
      "street": null,
      "city": "FUQUAY VARINA",
      "state": "NC",
      "zipcode": "275269278",
      "country": "UNITED STATES",
      "institution_phone": null,
      "departments": [
        {
          "department_name": "Unknown Department",
          "department_email": null,
          "department_phone": null,
          "people": [
            {
              "person_name": "SEAN  EKINS",
              "person_email": "nih_7983805@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 7983805)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            }
          ]
        }
      ]
    },
    {
      "institution_name": "UNIVERSITY OF CALIFORNIA, SAN FRANCISCO",
      "institution_type": "SCHOOLS OF MEDICINE",
      "street": null,
      "city": "SAN FRANCISCO",
      "state": "CA",
      "zipcode": "941432510",
      "country": "UNITED STATES",
      "institution_phone": null,
      "departments": [
        {
          "department_name": "PUBLIC HEALTH & PREV MEDICINE",
          "department_email": null,
          "department_phone": null,
          "people": [
            {
              "person_name": "fei  jiang",
              "person_email": "nih_12484647@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 12484647)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            }
          ]
        }
      ]
    },
    {
      "institution_name": "UNIVERSITY OF PITTSBURGH AT PITTSBURGH",
      "institution_type": "Domestic Higher Education",
      "street": null,
      "city": "PITTSBURGH",
      "state": "PA",
      "zipcode": "152133320",
      "country": "UNITED STATES",
      "institution_phone": null,
      "departments": [
        {
          "department_name": "Unknown Department",
          "department_email": null,
          "department_phone": null,
          "people": [
            {
              "person_name": "Marlene  Behrmann",
              "person_email": "nih_1897930@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 1897930)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            }
          ]
        },
        {
          "department_name": "PSYCHIATRY",
          "department_email": null,
          "department_phone": null,
          "people": [
            {
              "person_name": "HELMET Talib KARIM",
              "person_email": "nih_15085352@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 15085352)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            }
          ]
        },
        {
          "department_name": "INTERNAL MEDICINE/MEDICINE",
          "department_email": null,
          "department_phone": null,
          "people": [
            {
              "person_name": "Walid F. Gellad",
              "person_email": "nih_10407141@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 10407141)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            }
          ]
        }
      ]
    },
    {
      "institution_name": "WEILL MEDICAL COLL OF CORNELL UNIV",
      "institution_type": "SCHOOLS OF MEDICINE",
      "street": null,
      "city": "NEW YORK",
      "state": "NY",
      "zipcode": "100654805",
      "country": "UNITED STATES",
      "institution_phone": null,
      "departments": [
        {
          "department_name": "PSYCHIATRY",
          "department_email": null,
          "department_phone": null,
          "people": [
            {
              "person_name": "LOGAN  GROSENICK",
              "person_email": "nih_9260502@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 9260502)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            }
          ]
        }
      ]
    },
    {
      "institution_name": "UNIVERSITY OF PENNSYLVANIA",
      "institution_type": "SCHOOLS OF MEDICINE",
      "street": null,
      "city": "PHILADELPHIA",
      "state": "PA",
      "zipcode": "191046205",
      "country": "UNITED STATES",
      "institution_phone": null,
      "departments": [
        {
          "department_name": "NONE",
          "department_email": null,
          "department_phone": null,
          "people": [
            {
              "person_name": "Michael Steven Yu-Shuan Yao",
              "person_email": "nih_78305570@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 78305570)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            }
          ]
        }
      ]
    },
    {
      "institution_name": "UNIVERSITY OF NORTH TEXAS",
      "institution_type": "BIOMED ENGR/COL ENGR/ENGR STA",
      "street": null,
      "city": "DENTON",
      "state": "TX",
      "zipcode": "762035017",
      "country": "UNITED STATES",
      "institution_phone": null,
      "departments": [
        {
          "department_name": "BIOSTATISTICS & OTHER MATH SCI",
          "department_email": null,
          "department_phone": null,
          "people": [
            {
              "person_name": "Serdar  Bozdag",
              "person_email": "nih_11554010@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 11554010)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            }
          ]
        }
      ]
    },
    {
      "institution_name": "UNIVERSITY OF WISCONSIN-MADISON",
      "institution_type": "BIOMED ENGR/COL ENGR/ENGR STA",
      "street": null,
      "city": "MADISON",
      "state": "WI",
      "zipcode": "537151218",
      "country": "UNITED STATES",
      "institution_phone": null,
      "departments": [
        {
          "department_name": "BIOMEDICAL ENGINEERING",
          "department_email": null,
          "department_phone": null,
          "people": [
            {
              "person_name": "Filiz  Yesilkoy",
              "person_email": "nih_16448077@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 16448077)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            }
          ]
        },
        {
          "department_name": "GENETICS",
          "department_email": null,
          "department_phone": null,
          "people": [
            {
              "person_name": "Mark W. Craven",
              "person_email": "nih_6407230@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 6407230)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            }
          ]
        }
      ]
    },
    {
      "institution_name": "PENNSYLVANIA STATE UNIV HERSHEY MED CTR",
      "institution_type": "SCHOOLS OF MEDICINE",
      "street": null,
      "city": "HERSHEY",
      "state": "PA",
      "zipcode": "170332360",
      "country": "UNITED STATES",
      "institution_phone": null,
      "departments": [
        {
          "department_name": "PUBLIC HEALTH & PREV MEDICINE",
          "department_email": null,
          "department_phone": null,
          "people": [
            {
              "person_name": "Yu-Han  Chiu",
              "person_email": "nih_15899764@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 15899764)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            }
          ]
        }
      ]
    },
    {
      "institution_name": "UNIVERSITY OF MEMPHIS",
      "institution_type": "SCHOOLS OF ARTS AND SCIENCES",
      "street": null,
      "city": "MEMPHIS",
      "state": "TN",
      "zipcode": "381520001",
      "country": "UNITED STATES",
      "institution_phone": null,
      "departments": [
        {
          "department_name": "CHEMISTRY",
          "department_email": null,
          "department_phone": null,
          "people": [
            {
              "person_name": "Qianyi  Cheng",
              "person_email": "nih_77904714@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 77904714)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            }
          ]
        }
      ]
    },
    {
      "institution_name": "ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI",
      "institution_type": "SCHOOLS OF MEDICINE",
      "street": null,
      "city": "NEW YORK",
      "state": "NY",
      "zipcode": "100296574",
      "country": "UNITED STATES",
      "institution_phone": null,
      "departments": [
        {
          "department_name": "INTERNAL MEDICINE/MEDICINE",
          "department_email": null,
          "department_phone": null,
          "people": [
            {
              "person_name": "Gabriele  Campanella",
              "person_email": "nih_78602757@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 78602757)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            }
          ]
        }
      ]
    },
    {
      "institution_name": "BOSTON CHILDREN'S HOSPITAL",
      "institution_type": "Independent Hospitals",
      "street": null,
      "city": "BOSTON",
      "state": "MA",
      "zipcode": "021155724",
      "country": "UNITED STATES",
      "institution_phone": null,
      "departments": [
        {
          "department_name": "Unknown Department",
          "department_email": null,
          "department_phone": null,
          "people": [
            {
              "person_name": "Kwonmoo  Lee",
              "person_email": "nih_10578469@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 10578469)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            }
          ]
        }
      ]
    },
    {
      "institution_name": "UT SOUTHWESTERN MEDICAL CENTER",
      "institution_type": "SCHOOLS OF MEDICINE",
      "street": null,
      "city": "DALLAS",
      "state": "TX",
      "zipcode": "753909105",
      "country": "UNITED STATES",
      "institution_phone": null,
      "departments": [
        {
          "department_name": "PEDIATRICS",
          "department_email": null,
          "department_phone": null,
          "people": [
            {
              "person_name": "Lakshmi  Raman",
              "person_email": "nih_11025029@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 11025029)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            }
          ]
        }
      ]
    },
    {
      "institution_name": "UNIVERSITY OF ILLINOIS AT CHICAGO",
      "institution_type": "SCHOOLS OF MEDICINE",
      "street": null,
      "city": "Chicago",
      "state": "IL",
      "zipcode": "606124305",
      "country": "UNITED STATES",
      "institution_phone": null,
      "departments": [
        {
          "department_name": "EMERGENCY MEDICINE",
          "department_email": null,
          "department_phone": null,
          "people": [
            {
              "person_name": "Neeraj  Chhabra",
              "person_email": "nih_15556443@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 15556443)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            }
          ]
        }
      ]
    },
    {
      "institution_name": "UNIV OF NORTH CAROLINA CHAPEL HILL",
      "institution_type": "SCHOOLS OF MEDICINE",
      "street": null,
      "city": "CHAPEL HILL",
      "state": "NC",
      "zipcode": "275995023",
      "country": "UNITED STATES",
      "institution_phone": null,
      "departments": [
        {
          "department_name": "INTERNAL MEDICINE/MEDICINE",
          "department_email": null,
          "department_phone": null,
          "people": [
            {
              "person_name": "Keia  Sanderson",
              "person_email": "nih_14907116@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 14907116)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            }
          ]
        },
        {
          "department_name": "OBSTETRICS & GYNECOLOGY",
          "department_email": null,
          "department_phone": null,
          "people": [
            {
              "person_name": "Metin Nafi Gurcan",
              "person_email": "nih_8637742@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 8637742)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            },
            {
              "person_name": "CHARLES DAVID PAGE",
              "person_email": "nih_7935014@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 7935014)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            },
            {
              "person_name": "Alison M Stuebe",
              "person_email": "nih_9714083@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 9714083)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            }
          ]
        }
      ]
    },
    {
      "institution_name": "NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC",
      "institution_type": "Independent Hospitals",
      "street": null,
      "city": "NEW YORK",
      "state": "NY",
      "zipcode": "100321007",
      "country": "UNITED STATES",
      "institution_phone": null,
      "departments": [
        {
          "department_name": "Unknown Department",
          "department_email": null,
          "department_phone": null,
          "people": [
            {
              "person_name": "Natalie  Bareis",
              "person_email": "nih_12578186@profiles.nih.gov",
              "person_phone": null,
              "bio": "NIH Investigator (profile 12578186)",
              "profile_url": null,
              "expertise_1": null,
              "expertise_2": null,
              "expertise_3": null,
              "main_field": null
            }
          ]
        }
      ]
    }
  ],
  "projects": [
    {
      "project_title": "Machine Learning for Ventricular Arrhythmias",
      "project_description": "Project Summary\n Ventricular tachycardia (VT) and fibrillation are leading causes of cardiac arrest, dizziness,\nsyncope and hospitalization in the United States and worldwide. However, the management of patients\nat risk for VT remains suboptimal despite scientific discoveries from basic to population science. In\nparticular, there is no framework to estimate which patients with VT are likely to respond to anti-\narrhythmic medications or ablation. Therapy is thus empirical. There is great excitement to use analysis\nof “big data” to personalize VT therapy, but this has not yet improved outcomes.\n This project develops a novel computational approach to personalize VT therapy that combines\nmachine learning in large registries with computational models. Machine learning will be applied to data\nacross biological scales that span bedside, laboratory and non-invasive imaging, to predict which\npatients are likely to respond to therapy. Computer models will be used to estimate if a given patient's\nheart is likely to support VT before versus after therapy. We will validate results in large external\nregistries from different Institutions. We have 3 specific aims: (1) To develop a computational pipeline to\npredict response to VT ablation using bedside, laboratory and non-invasive imaging; (2) To use machine\nlearning of clinical data and non-invasive imaging to identify which patients with VT will respond to anti-\narrhythmic medications in a large database; (3) To combine computational approaches to estimate the\nrelative likelihood that a given patient will respond to various forms of therapy. Results from each Aim will\nbe tested in independent external registries. We will probe computational models to identify clinical\nphenotypes that could be applied at the bedside.\n This project will provide immediate clinical impact for patients with VT. We will combine machine\nlearning with physics-based computer models in large registries at Stanford and External centers. We will\nreduce computational bias using FAIR methods (Findable, Accessible, Interoperable, and Reusable),\nand make tools freely available per the 2018 NIH Strategic Plan for Data Science. Our team comprises\nexperts in clinical and basic electrophysiology, imaging, machine learning, bioengineering and statistics.\nThe project is very feasible.",
      "project_tags": "SCHOOLS OF MEDICINE",
      "start_date": "2025-11-13",
      "end_date": null,
      "external_id": "3R01HL162260-03S1"
    },
    {
      "project_title": "Designing Personalized Formulations with Machine Learning",
      "project_description": "The design of drug formulations is an essential part of pharmaceutical development to enable the safe and effective delivery of medications. Unfortunately, formulation optimization is currently done using a trial-and-error approach or by adhering to already established formulation strategies following a one-size-fits-all mindset. This has resulted in formulations that are simple and only ensure appropriate physical properties such as shelf life and liberation. Complex, targeted formulations can increase the safety and efficacy of medications, but such systems are expensive to design, manufacture, and administer. Here, we describe our goals to expand and augment our efforts in developing innovative machine learning methods and integrate them with experimental workflows for the design of novel, targeted drug formulations. We will specifically focus on the machine learning-guided design of (1) functional excipients that prevent microbiome metabolism, (2) targeted self-assembling nanoparticles, and (3) tissue-selective prodrugs. Our machine learning models will enable us to circumvent billions of otherwise necessary trial-and-error experiments by predicting the most promising candidates for experimental validation. This allows us to systematically explore novel drug delivery systems to identify better solutions. Our in vitro and in vivo experiments will validate our predictions and provide pre-clinical data for innovative drug delivery solutions positioned for further translation. We expect that our platform will enable the rapid and effective design of advanced drug delivery solutions to create safer and more efficacious therapeutics.",
      "project_tags": "BIOMED ENGR/COL ENGR/ENGR STA",
      "start_date": "2025-11-13",
      "end_date": null,
      "external_id": "5R35GM151255-03"
    },
    {
      "project_title": "Machine Learning for Ventricular Arrhythmias",
      "project_description": "Project Summary\n Ventricular tachycardia (VT) and fibrillation are leading causes of cardiac arrest, dizziness,\nsyncope and hospitalization in the United States and worldwide. However, the management of patients\nat risk for VT remains suboptimal despite scientific discoveries from basic to population science. In\nparticular, there is no framework to estimate which patients with VT are likely to respond to anti-\narrhythmic medications or ablation. Therapy is thus empirical. There is great excitement to use analysis\nof “big data” to personalize VT therapy, but this has not yet improved outcomes.\n This project develops a novel computational approach to personalize VT therapy that combines\nmachine learning in large registries with computational models. Machine learning will be applied to data\nacross biological scales that span bedside, laboratory and non-invasive imaging, to predict which\npatients are likely to respond to therapy. Computer models will be used to estimate if a given patient's\nheart is likely to support VT before versus after therapy. We will validate results in large external\nregistries from different Institutions. We have 3 specific aims: (1) To develop a computational pipeline to\npredict response to VT ablation using bedside, laboratory and non-invasive imaging; (2) To use machine\nlearning of clinical data and non-invasive imaging to identify which patients with VT will respond to anti-\narrhythmic medications in a large database; (3) To combine computational approaches to estimate the\nrelative likelihood that a given patient will respond to various forms of therapy. Results from each Aim will\nbe tested in independent external registries. We will probe computational models to identify clinical\nphenotypes that could be applied at the bedside.\n This project will provide immediate clinical impact for patients with VT. We will combine machine\nlearning with physics-based computer models in large registries at Stanford and External centers. We will\nreduce computational bias using FAIR methods (Findable, Accessible, Interoperable, and Reusable),\nand make tools freely available per the 2018 NIH Strategic Plan for Data Science. Our team comprises\nexperts in clinical and basic electrophysiology, imaging, machine learning, bioengineering and statistics.\nThe project is very feasible.",
      "project_tags": "SCHOOLS OF MEDICINE",
      "start_date": "2025-11-13",
      "end_date": null,
      "external_id": "5R01HL162260-03"
    },
    {
      "project_title": "Interpretable machine learning for understanding the neural control of movement",
      "project_description": "Modern machine learning can fit complex models that make accurate predictions. However, understanding the brain with standard machine learning is a great challenge. A critical impediment is that it is often difficult to understand the inner workings of these models. There is thus a great need for more interpretable machine learning methods for neuroscience, in which the inner workings of the model relate to neural structure or function. The proposed research will develop interpretable machine learning methods for studying the neural control of movement. Through close collaboration with the experimental lab of Dr. Churchland, these methods will be applied to answer three central questions in motor control. In the first two aims, the research investigates how flexibly spinal motor neurons can be controlled, and how activity in motor cortex controls muscle activity across a wide range of movements. Beyond increasing scientific knowledge, answering these two questions could enhance brain computer interfaces for restoring control to those with motor impairments. In the third aim, the research investigates how multiple neural populations interact with each other to plan and generate movement. This question is relevant to many neurological disorders, in which communication between brain areas is disrupted. During the K99 phase of this award, occurring within Columbia’s vibrant neuroscience community, the applicant will receive additional training in computational techniques from Drs. Paninski and Cunningham, and additional experimental training from Dr. Churchland. This training will provide the necessary experience for the applicant to be successful in this work and to successfully start an independent lab at the interface of machine learning and the neural control of movement.",
      "project_tags": "SCHOOLS OF MEDICINE",
      "start_date": "2025-11-13",
      "end_date": null,
      "external_id": "5R00NS119787-05"
    },
    {
      "project_title": "Machine Learning and Image Analysis Core",
      "project_description": "PROJECT SUMMARY/ ABSTRACT MACHINE LEARNING AND IMAGE ANALYSIS CORE\nThe Machine Learning and Image Analysis Core of The Jackson Laboratory Nathan Shock Center (JAX NSC)\nuses cutting-edge data science approaches to develop novel aging biomarkers to support JAX NSC studies and\nthe broader aging community. Our studies leverage the diversity of our mouse models to ensure the\ngeneralizability of our biomarkers and undertake outreach activities to support their adoption. The Specific Aims\nof the Machine Learning and Image Analysis Core are: Aim 1. Adapt a quantitative image analysis pipeline\nfor the analysis of aged heart, liver, lung, spleen, and ovarian tissues by training and validating\nclassifiers. This Aim continues our work from the current funding period, where we developed first-in-class\ndigital pathology models to predict tissue aging and extensively developed new neural network architectures to\nsupport model interpretation. We now have a mature, cutting-edge framework to extend these efforts to multiple\ntissues, including ovarian tissue, that will be generated during the next funding cycle. Aim 2. Adapt a\nquantitative machine learning pipeline for the analysis of hematology signatures across ages by training\nand establishing classifiers. We will extend our biomarker development efforts to clinically translatable\nhematology analyzer data (i.e., scattergrams) from our diverse aging mouse cohorts, using machine learning\napproaches to develop blood biomarkers of aging. Aim 3. Develop and distribute open-source, user-friendly\npackages for both the quantitative and discovery pipelines with online training to the geroscience\ncommunity. Once our pipelines have been trained and validated, we will make them publicly available as open\nsource to the community. This resource sharing will stimulate their use and will allow other groups to extend and\nimprove upon our work. The core supports aging research by generating novel biomarker resources from our\nstudies that are designed to support a broad range of aging research activities.",
      "project_tags": "Research Institutes",
      "start_date": "2025-11-13",
      "end_date": null,
      "external_id": "2P30AG038070-16"
    },
    {
      "project_title": "Machine Learning and Control Principles for Computational Biology",
      "project_description": "Summary/Abstract\nWith our increasing ability to measure biological data at scale and the digitalization of health records,\ncomputational thinking is becoming ever more important in the biological science and healthcare. The research\ndirections proposed in this grant look to build robust machine learning models and tool for computational biology\nby including principles and analysis from other engineering fields, like control, that have a proven record of\nincorporating robustness into the systems they have automated. This increased robustness will save resources\nduring the development of these machine learning models. It will also lead to more reliable diagnostics, clinical\ntools, and machine learning based biological discoveries. We have proposed three future research directions at\nthe intersection of machine learning, control, and computational biology (a) modeling dynamical systems, (b)\nrobust optimization schemes (c) control principles for in vivo modeling of microbial communities. The first\nproposed research area involves the development of flexible models for performing inference on dynamical\nsystems models with time-series data. Dynamical systems models are able to learn mathematically causal\nrelationships between variables, compared to other models whose parameters may only have correlative\nrelationships. Our flexible models will be differentiable allowing them to be trained using the same efficient\nalgorithms and hardware that have propelled deep learning models into the spotlight. These differentiable\nmethods will allow for us to more easily integrate the uncertainty associated with biological measurements into\nour models. The second research area looks to develop more robust gradient optimization algorithms, the work\nhorse for training deep neural networks. Many of the popular algorithms used to train deep neural networks were\nnot explicitly designed to be robust. By developing more robust optimization techniques machine learning models\ntrained on disparate data sets at different hospital or labs will be more reproducible and will require less time for\ntuning parameters, ultimately saving resources as well. These robust optimization techniques will also aid in the\ncertification of machine learning based tools that will ultimately be deployed in the clinic. The third research area\nwe propose is an approach for the discovery and design of robust microbial communities. Communities of\ncommensal, or engineered, bacteria have long been proposed as alternative therapies for the treatment of gut\nrelated illness (“bugs as drugs”). We propose a top down approach to identifying putative microbial consortia\nmembers from time-series experiments with germ free mice colonized by complex flora. By beginning the\nconsortia design process in vivo we hope to overcome the challenge that many other attempts at consortia\nconstruction have encountered where in vitro designed communities do not reproduce their intended properties\nonce transferred into living host organisms. The tools from this work will be built using open access software and\nall data will be made easily accessible and explorable to the public.",
      "project_tags": "Independent Hospitals",
      "start_date": "2025-11-13",
      "end_date": null,
      "external_id": "5R35GM143056-05"
    },
    {
      "project_title": "Multiethnic machine learning brain signatures of ADRD",
      "project_description": "PROJECT SUMMARY / ABSTRACT\nThe underlying pathology of Alzheimer's disease and related dementias (ADRDs) accumulates gradually over\ndecades, making the identification of non-invasive, sensitive biomarkers in the preclinical stage a critical public\nhealth priority. Harnessing advanced analytic methods, our team and others have established neuroimaging\nsignatures of advanced brain aging (Spatial Pattern of Atrophy Recognition of Brain Aging, SPARE-BA) and\nfunctional decline (fSPARE-BA), and ADRDs (SPARE-AD and SPARE-Small vessel disease), which predict\nincident cognitive decline. Unfortunately, most research to date has been conducted in predominantly non-\nHispanic white populations, which limits the ability to generalize results to the diverse ethnoracial makeup of the\nUnited States' growing aging demographic. If current trends continue, machine learning models will primarily be\ntrained in ethnically imbalanced datasets, leading to biases that may affect clinical relevance. Thus, the primary\naims of the current proposal are to: leverage an ethnically diverse neuroimaging consortium to build new machine\nlearning models trained by data from ethnically well-balanced populations, derive sensitive and specific\nneuroimaging signatures of brain aging and ADRD, and evaluate whether they can be practical non-invasive\nbiomarkers of incident cognitive decline, mild cognitive impairment (MCI), and dementia across ethnoracial\ngroups. We propose to leverage the rich clinical and neuroimaging (structural MRI and resting-state functional\nMRI) data within the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium,\nincluding the Atherosclerosis Risk in Communities Study (ARIC), the Cardiovascular Health Study (CHS), the\nGenetics of Brain Structure and Function Study (GOBS), the Framingham Heart Study (FHS), the Vascular\nContributions to Cognitive Impairment and Dementia consortium (MARK-VCID) and the Multi-Ethnic Study of\nAtherosclerosis (MESA). We will leverage a collaborative research framework across existing longitudinal\ncohorts to address unanswered questions contributing to disparities in ADRD burden. Machine learning\nalgorithms will be applied to brain imaging data of over 7,200 non-Hispanic Whites, 1,400 Blacks, and 1,425\nHispanics to address our Specific Aims: 1) Generate and evaluate clinical utility of machine learning-based\nsignatures of brain aging and ADRD for each race/ethnic group and uncover multidimensional heterogeneity in\naging across groups; 2) Examine associations of vascular risk factors with the derived machine learning-based\nbrain signatures of ADRD by race/ethnicity, and 3) Explore blood-based biomarker predictors of these machine\nlearning-based brain signatures by ethnoracial group to elucidate underlying biological mechanisms. Further, we\nwill share our robust machine learning models together with implementation software with the scientific\ncommunity. This project will develop and validate neuroimaging markers with robust predictive utility for incident\ncognitive decline and to identify underlying pathophysiologic pathways, expanding opportunities for novel\nintervention development across diverse ethnoracial cohorts.\nii",
      "project_tags": "SCHOOLS OF MEDICINE",
      "start_date": "2025-11-13",
      "end_date": null,
      "external_id": "5R01AG080821-04"
    },
    {
      "project_title": "Explainable Machine Learning to Guide Prefrontal Brain Stimulation",
      "project_description": "Project Summary\nBrain stimulation has shown great therapeutic promise for a wide range of neurological and psychiatric disorders. In\naddition to advanced engineering tools, successful implementation of brain stimulation requires a comprehensive un-\nderstanding of how this treatment drives changes in network dynamics and connectivity at a large scale and across\nmultiple brain areas. It also requires the design of controllers that can relate stimulation effects to behavior and function.\nTo achieve these goals, we will develop novel explainable machine learning models for psychiatric brain stimulation.\nTo do so, we put forward three overarching goals. First, we aim to learn biologically plausible and ﬂexible functional\nconnectivity models from electrocorticography (ECoG) data. Then, we plan to develop a computational model based\non a deep graph convolutional net to learn associations between ECoG data and network-scale connectivity. We will\nthen design a machine learning based guide for psychiatric brain stimulation. Finally, we will use our tools to under-\nstand how the network evolves through time. To achieve these goals, the project brings together an interdisciplinary\nteam of investigators with unique expertise in artiﬁcial intelligence and machine learning, computational and theoretical\nneuroscience, network science and biostatistics, bioengineering and brain stimulation experiments, and interventional\npsychiatric and neural engineering. The team will lead experimental and computational efforts that will produce ad-\nvanced explainable machine learning solutions informed by brain stimulation experiments and utilize these tools to\ndesign more efﬁcient and effective brain stimulation therapies.",
      "project_tags": "SCHOOLS OF ARTS AND SCIENCES",
      "start_date": "2025-11-13",
      "end_date": null,
      "external_id": "5R01MH125429-04"
    },
    {
      "project_title": "Robust, Generalizable, and Fair Machine Learning Models for Biomedicine",
      "project_description": "Project Summary\n Modern machine learning approaches have attained substantial success in\npattern recognition and high-dimensional data analyses. However, these algorithms\nheavily rely on association discovery, which cannot elucidate the mechanisms\nunderpinning the observed correlations and suffers from limited generalizability. To\naddress this challenge, the Yu Lab focuses on the development of robust and\ngeneralizable machine learning approaches to integrate various types of biomedical\ndata, including multi-omics, pathology, and phenotypic information. The goal of the next\nfive years is to develop novel computational methods that connect machine learning\nalgorithms with causal inference methodologies to better understand the molecular\nmechanisms underpinning disease pathology and enable fair and robust predictions of\ndrug response and toxicity. The overall vision of the proposed research program is to\nestablish generalizable data-driven methods to transform biomedical data into robust\nprediction and mechanistic models. The proposed approach will systematically connect\ndiverse biomedical signals to extract previously unknown knowledge on the molecular\nmechanisms and derive reliable prediction models for the effects of medications. The\nproposed approaches are innovative because they depart from the status quo by\nincorporating advanced causal inference techniques with data-driven algorithms to\nenhance mechanistic and predictive modeling. This research program is significant\nbecause it is expected to improve our understanding of disease pathology and provide a\nfair and generalizable informatics framework for drug response and adverse effects\nprediction in diverse populations. The proposed research activities will open new\nresearch horizons by establishing a new machine learning platform for generating\nreliable predictions, which will vertically advance molecular biology, pharmacology, and\ncomputational research in biomedicine.",
      "project_tags": "SCHOOLS OF MEDICINE",
      "start_date": "2025-11-13",
      "end_date": null,
      "external_id": "5R35GM142879-05"
    },
    {
      "project_title": "Machine learning approaches for the discovery, repurposing, and optimization of natural products with therapeutic potential",
      "project_description": "Project Summary\nNatural products from bacteria, fungi, and plants have long been a rich source of useful molecules. However,\ndue to their complex structures, it is difficult to screen many analogs of natural products to truly understand the\nrules governing the relationship between their structure and activity. We will address this challenge by developing\nmachine learning methods that can functionally model the structure-activity relationships (SAR) of natural\nproducts and aid in the design of biosynthetic pathways that can synthesize natural product analogs. Therefore,\nwe will develop methods both for prioritizing natural products that are most likely to be useful as therapeutics for\nactivity screens and for biosynthesizing natural products of interest.\nMachine learning is a powerful computational technique that enables computers to make inferences from data.\nThere is a wealth of sequence, structure, and activity data available for biological molecules that we can use to\nbuild machine learning models to make predictions about the behavior of biochemical systems. Even machine\nlearning algorithms that are not perfectly accurate can be extremely useful for drug discovery efforts. It is possible\nto screen orders of magnitude more compounds using machine learning than in high-throughput screens.\nMachine learning can therefore be used as an initial filter to increase hit rates in screens.\nOur first project will apply machine learning to study natural product SARs. We will take two approaches, a\ngenetic and chemical structure approach. In the genetic approach we will validate correlations between\nbiosynthetic genes and natural product activity that we have previously observed and confirm that the correlation\nextends to chemical substructures installed by the biosynthetic genes. In the chemical structure approach, we\nwill investigate the ability of graph neural networks to predict natural product properties.\nOur second project will focus on developing machine learning and other computational tools for designing\nbiosynthetic gene clusters (BGCs) to biosynthesize novel natural product-like molecules. We will first focus on\nRibosomally Synthesized and Posttranslationally modified Peptides (RiPPs) and develop methods to predict\ncompatible modifying enzyme-leader peptide pairs. To do this we will use molecular modeling, Statistical\nCoupling Analysis (SCA), and machine learning. After validating our methods on RiPPs, we will turn our attention\nto more difficult classes of BGCs, such as nonribosomal peptide synthetases (NRPS) and polyketide synthases\n(PKS).\nOur third project is the development of methods for designing RiPP-based protein-protein interaction (PPI)\ninhibitors. We will develop both molecular modeling and machine learning methods for predicting optimal RiPP\nsequences for inhibiting a PPI of interest. We will then validate and collect additional training data for these\npredictions using directed evolution experiments.",
      "project_tags": "SCHOOLS OF ARTS AND SCIENCES",
      "start_date": "2025-11-13",
      "end_date": null,
      "external_id": "5R35GM146987-04"
    },
    {
      "project_title": "Integrative Machine Learning for Common Fund Spatial Omics",
      "project_description": "PROJECT SUMMARY / ABSTRACT\nThe NIH Common Fund supports transformative programs that generate large-scale datasets crucial for the\nbroad biomedical research community. The emerging spatial transcriptomics in Common Fund programs\nprovide invaluable insights into cellular diversity and tissue organization. However, integrating and analyzing\nthese diverse datasets remains a significant challenge. To address this gap, we propose developing new\nmachine learning methods to analyze spatial transcriptome data from multiple NIH Common Fund programs, in\nparticular, HuBMAP and SenNet. First, we will develop machine learning methods for integrative analysis of\nmultiple spatial transcriptome datasets. This will include creating a scalable, platform-agnostic framework using\npretrained single-cell RNA-seq foundation models to integrate diverse spatial transcriptome datasets and a\nmethod to analyze spatial gene programs across multiple samples. Second, we will develop machine learning\nmethods to reveal the underlying mechanisms of spatial gene expression. This will involve creating a\ntransformer-inspired model to disentangle intrinsic cellular factors from intercellular interactions and a\nframework to identify transcription factors modulating spatial gene programs. Collectively, the methods and\ntools developed in this project will significantly enhance the utility of existing NIH Common Fund spatial\ntranscriptomics datasets and facilitate integration with other related programs. This will drive forward our\nunderstanding of spatial gene regulation and its role in health and disease, aligning with the NIH Common\nFund’s mission to support transformative research with broad scientific impact.",
      "project_tags": "SCHOOLS OF ARTS AND SCIENCES",
      "start_date": "2025-11-13",
      "end_date": null,
      "external_id": "1R03OD039980-01"
    },
    {
      "project_title": "Machine Learning Models of Appropriate Medevac Utilization in Rural Alaska",
      "project_description": "PROJECT SUMMARY / ABSTRACT\nThe purpose of this award is to provide Dr. Brian Rice, Assistant Professor of Emergency Medicine at Stanford\nUniversity, the support necessary for his transition from a junior investigator into an independent clinician-\nscientist using applied biomedical informatics to address health disparities. Dr. Rice is an emergency medicine\nphysician with an advanced degree in epidemiology and global health, and a background in computer\nprogramming and artificial intelligence. His long-term goal is to utilize his interdisciplinary training to develop\nand implement machine learning tools to empower precise, high-value clinical decision-making surrounding\nemergency care and transport in historically disadvantaged populations. His training activities focus on\nadvancing his ability to apply biomedical informatics to address health disparities via these training objectives:\n1) expanding his skills in data management and computational statistics 2) learning methods for community-\nengaged and participatory approaches to health disparities research, and 3) acquiring new skills machine\nlearning and classification model building. The candidate has convened a mentorship team that includes Dr.\nTina Hernandez-Boussard, a biomedical artificial intelligence expert with a focus on improving transparency\nand minimizing bias in machine learning models to make them more equitable and generalizable, and Dr.\nStacy Rasmus, a leading Alaska Native behavioral scientist with extensive experience successfully conducting\ncommunity-engaged qualitative research in rural Alaska. The research proposal builds off the candidate’s prior\nwork with air medical evacuation (medevacs) in rural Alaska which established the central hypothesis that\nmedevacs can be classified as appropriate or inappropriate by machine learning models built on outcome data\nand enriched by qualitative methods. This central hypothesis will be tested by the following specific aims: 1)\ndefine the burden and outcomes of medevacs in rural Alaska; 2) identify key context-specific contributors to\nmedevac utilization in rural Alaska; and 3) develop machine learning models to classify appropriateness of\nmedevac utilization in rural Alaska. The research proposed in this application is innovative because it employs\naccepted methods of machine learning classification modelling and applies them to novel fields of medevac\nand Alaska Native health disparities. The significance of the proposed training grant is it will provide the data\nand the skills required for Dr. Rice to subsequently study the implementation of these models as a decision tool\nin a future R01-level application. Ultimately, this continuum of research has the potential to decrease expenses\nand improve safety by redirecting medevac resources towards patients whose time-sensitive conditions benefit\nfrom medevacs and away from patients that incur risk and cost without benefit, both in Alaska Native\ncommunities in rural Alaska and for all Americans living in rural regions nationwide.",
      "project_tags": "SCHOOLS OF MEDICINE",
      "start_date": "2025-11-13",
      "end_date": null,
      "external_id": "5K08MD016445-04"
    },
    {
      "project_title": "Machine Learning to Modulate Influenza Immunity",
      "project_description": "PROJECT SUMMARY/ABSTRACT\nIn this proposal, we will leverage \"Machine Learning to Modulate Influenza Immunity\" by developing and\nimplementing computational tools tailored towards the design of broadly protective vaccines against influenza\nviruses. Machine Learning (ML)-based algorithms pioneered by us and others have revolutionized protein\nstructure prediction (AlphaMask, AxIEM, AlphaFold, or ESM) and design (ProteinMPNN, Rosetta) and have\nimproved accuracy and speed of protein engineering. Here, we will integrate Artificial Intelligence/Machine\nLearning (AI/ML) and traditional computational biology to create a novel class of immunogen candidates that\novercome the inefficacy of current influenza vaccines which fail to elicit broad and long-lasting protection.\nWe will explore three immunogen design strategies: 1.) germline-targeting on the lateral patch of hemagglutinin\n(HA), one of the most conserved epitopes in the highly immunogenic HA head domain; 2.) HA\nheterotrimerization to create immunogens exposing various HA types and/or subtypes; and 3.)\nepitope-focusing to shift the immune response from highly variable regions to more conserved epitopes.\nEach aim will develop a computational pipeline with new algorithms for their respective immunogen design\nobjectives that will be iteratively refined by experimental feedback, thereby successively improving the\nperformance of the computational tools. In vitro experiments will provide high-throughput feedback from\nmammalian surface display, including deep mutational scanning of germline-targeting mutations and deep\nglycosylation scanning to evaluate the potential for immune evasion through hyper-glycosylation of HA. These\nlarge datasets will be integrated in AI/ML tools to extend predictions to other strains and further guide future\nvaccine design. To validate the effect of novel immunogen candidates, we will employ human Ig loci transgenic\nmice capable of producing fully humanized B-cell receptors. To simulate the effects of original antigenic sin, a\nmechanism in which primary contact with a novel immunogen has a lasting impact on subsequent antibody\nresponses, we will analyze immunogenicity in animals pre-immunized with wildtype HA, thereby obtaining\ninsights into the interaction of computationally designed immunogens with human-like antibody responses. The\nin vivo experiments will be complemented by ex vivo sorting of human naïve and memory B cells with\ncomputationally designed immunogens. All experiments will be supported by structural characterization\nthrough computations, X-ray crystallography, electron microscopy, and mass spectrometry to identify\ndeterminant mechanisms of protections. The efficacy of promising immunogens will be tested in lethal\nchallenge experiments.\nWe ensure the AI/ML-based computational tools developed in this project are readily available free-of-charge\nand transferable to other immunogen design challenges. The deepened understanding of the interaction of the\nimmune system with rationally designed immunogens will support the future development of vaccines.",
      "project_tags": "SCHOOLS OF ARTS AND SCIENCES",
      "start_date": "2025-11-13",
      "end_date": null,
      "external_id": "1U01AI187059-01"
    },
    {
      "project_title": "Using Causal Machine Learning Methods to Inform Tobacco Regulatory Science",
      "project_description": "PROJCT SUMMARY/ABSTRACT\nInconsistent findings regarding whether and how E-cigarette (EC) use influences subsequent tobacco use\nbehaviors complicate evidence-based tobacco regulation. Among youth, EC use is associated with greater risk\nof transitioning to combustible cigarette (CC) smoking, but estimated effect sizes of EC exposure vary\nsubstantially across studies. Among adults who currently smoke CCs, ECs show potential to help quit CC\nsmoking in some studies but not in others. These inconsistent findings may be due in part to a preponderance\nof observational studies, use of small size cross-sectional data, and inadequate control for covariates, Further,\ndespite considerable heterogeneity in the size of estimated EC exposure effects, whether specific\ncharacteristics modify the EC exposure effects has been largely ignored in literature. Understanding how ECs\ninfluence subsequent CC smoking, particularly among vulnerable subgroups (e.g., age, gender), and their\nintersectionality, will help inform regulatory activities that address tobacco-related health disparities. Lastly, it is\nunclear whether estimated EC exposure effects from a certain population subgroup or at a certain time can be\ngeneralized to different subgroups or times. Generalizable EC exposure effects could provide critical evidence\nfor tobacco regulators. To address these knowledge gaps, this study aims to use causal machine learning\nmethods to determine the influence of ECs on subsequent CC smoking, in overall US youth and adult\npopulations and in vulnerable subgroups, and to explore methods for estimating generalizable EC exposure\neffects. A secondary analysis of the longitudinal Population Assessment of Tobacco and Health study will be\nconducted to address the following specific aims. Aim 1: Determine average exposure effects of EC use on\nsubsequent CC smoking in youth and adults. Aim 2: Determine heterogeneous EC exposure effects among\nvulnerable subgroups (age, gender, poverty, race/ethnicity). Aim 3: Evaluate the performance of causal\nmachine learning methods to generalize EC exposure effects using both simulated and PATH Study data. To\nsuccessfully accomplish these aims and develop into an independent methodologist in tobacco regulator\nscience (TRS), I will obtain training in the following areas: 1) TRS theories and measures, especially health\ndisparities in TRS; 2) Causal inference methods for evaluating exposure effects; and 3) Machine learning skills\nfor high-dimensional data analysis. During the award period, I will be supported in my research and training\ngoals by my institution and interdisciplinary mentoring team, which consists of experts in the fields of TRS,\ncausal inference, machine learning, and health disparities. The K01 research and training experience will result\nin an R01 with the overarching goal of extending causal machine learning methods for generalization to\naddress more complex real-world questions. In the long term, I will bring TRS, machine learning methods,\nand causal inference together to address pressing issues in TRS. This effort will put causal machine learning\nmethods in the hands of tobacco researchers and facilitate the use of complex data to inform FDA regulations.",
      "project_tags": "SCHOOLS OF PUBLIC HEALTH",
      "start_date": "2025-11-13",
      "end_date": null,
      "external_id": "5K01DA058408-03"
    },
    {
      "project_title": "SCH: Quantifying and mitigating demographic biases of machine learning in real world radiology",
      "project_description": "The application of modern machine learning algorithms in radiology continues to grow, as these tools represent potential huge improvements in efficiency, accessibility and accuracy of diagnostic and screening tools. At the same time, these increasingly complex machine learning models can result in predictions of different accuracies in different settings, such as those resulting from different imaging acquisition protocols, different imaging equipment, or different phenotypic tissue characteristic. Such lack of robustness of predictive models are particularly important in public health applications that focus on large scale population-based screening, as in cancer screening for breast and lung cancer. Thus, it is paramount to understand these sources of variability in machine learning screening algorithms, as well as developing methods to mitigate them. This proposal will develop tools to quantify, correct, and analyze the sources of prediction errors in algorithms in relation to different sources of variability in data acquisition in real world settings. In particular, we will develop analysis and algorithms to quantify the difference in predictive performance by a machine learning model in situations where information about the sources of variability itself (such as acquisition location, tissue characteristics, and acquisition protocols) are not directly observable, and we will provide algorithms that correct for their worst-case difference in predictive power. We will analyze our tools under distribution shifts, whereby differences across medical centers exist, as is common in large scale cancer screening programs. This project will also perform inference on the training samples and features most highly associated with difference in predictive power, thereby providing guidance on the development of solutions to prevent these limitations in the future. Our tools will be validated on a variety of large real-world radiology datasets spanning multiple imaging modalities, including general chest X-ray datasets that include lung cancer diagnoses (CheXpert and MIMIC-CXR), as well as the Emory Breast Cancer Imaging Dataset (EMBED) and the National Lung Cancer Screening Trial, evaluating and correcting disparities for predictive algorithms with different acquisition protocols, technical equipment, and data quality. The results of this project will establish critical knowledge about the propensity of machine learning models for medical imaging diagnosis to be sensitive to imaging settings, as well as foundational tools to quantify and mitigate these limitations in potentially game-changing technologies.",
      "project_tags": "BIOMED ENGR/COL ENGR/ENGR STA",
      "start_date": "2025-11-13",
      "end_date": null,
      "external_id": "5R01CA287422-03"
    },
    {
      "project_title": "The Short Course on the Application of Machine Learning for Automated Quantification of Behavior",
      "project_description": "PROJECT SUMMARY \nElucidating the mechanism and function of neural encodings and circuit dynamics has been a major challenge in neuroscience and behavioral analyses. However, quantitative behavior analysis has dramatically accelerated and improved with the implementation and application of new machine learning methods, including new deep learning-based methods to track animals at high temporal and spatial resolution. This technology has broad current and potential application that will impact a breadth of fields that have direct relevance and impact on studies of human health and disease, including the fields of neuroscience, behavior, genetics, psychiatry, and biomedicine. However, several roadblocks limit the widespread adoption of these tools and analyses. First, many tracking and behavior analysis packages require a high level of computational expertise and are thus limited in application to expert labs. Second, with high-resolution data streams, quantitating behavior requires new statistical tools and proper modeling of data. Since the application of machine learning to behavioral analyses is an emerging and key methodology, we recognize an unmet need for investigators in a variety of relevant fields to learn the fundamentals of its rigorous use. Thus, to train a new generation of interdisciplinary researchers at the interface of neuroscience, machine learning, and behavior, we propose to establish an annual 4-day workshop that brings together experts in quantitative behavior, computer vision, and experimental design to provide a practical introduction to the field of quantitative neuroethology and behavior: we propose the unique and timely interdisciplinary course The Short Course on the Application of Machine Learning for Automated Quantification of Behavior at the Jackson Laboratory (JAX). This Short Course will provide attendees (in-person and virtually) with; information on the state-of-the-art of machine learning based behavior quantitation, the fundamentals of behavior quantitation, hands-on workshops and data analysis, a forum for student-teacher interaction for networking, and training at the leading edge of computational ethology. Students will emerge from the course with the ability to: 1) design a high quality, adequately powered behavior experiment; 2) select and install a suitable platform for high-resolution analysis of animal behavior; 3) deploy a behavior data analysis strategy, including collecting new training datasets, training analysis software, and validating performance on held-out data; and 4) run workflows/pipelines that are necessary to analyze their data following extraction. To achieve this, we propose: Aim 1. To develop and deliver a 4-day workshop to train scientists on application of machine learning to animal behavior quantitation. Aim 2. To create an environment that will expand the field of quantitative behavior analysis by fostering idea generation, discussion, and collaboration to yield new discoveries, broader applications, and advance technology development. Aim 3. Foster the recruitment and development of junior investigators in neuroscience, behavioral genetics, and quantitative analysis of animal behavior.",
      "project_tags": "Research Institutes",
      "start_date": "2025-11-13",
      "end_date": null,
      "external_id": "5R25MH129298-04"
    },
    {
      "project_title": "Biology-aware machine learning methods for characterizing microbiome genotype and phenotype",
      "project_description": "PROJECT SUMMARY\n1 The Mirarab laboratory designs leading computational methods for answering biological and biomedical ques-\n2 tions, focusing on scalability and accuracy. These methods span several areas (e.g., microbiome proﬁling,\n3 multiple sequence alignment, and phylogenomics), and a common thread among them is evolutionary mod-\n4 eling. The lab has developed scalable and accurate methods for reconstructing evolutionary histories (i.e.,\n 5 phylogenies) and using these histories in downstream biomedical applications. Reconstructing phylogenies is a\n 6 fundamental goal and a precursor to many biological analyses. Methods developed by this lab (e.g., ASTRAL)\n7 are at the forefronts of modern genome-wide phylogenetics. Moreover, biomedical research increasingly uses\n8 evolutionary histories in diverse areas like microbiome analyses, immunology, epidemiology, and comparative\n9 genomics. While the lab has previously focused more on inferring species histories, it has recently started\n10 to shift its focus to developing methods for microbiome analyses. The inference and the use of evolutionary\n11 histories in analyzing environmental microbiome samples present a unique set of challenges.\n12 In the next ﬁve years, the Mirarab lab will focus on designing, testing, and applying improved methods for\n13 statistical analyses of microbiome data. These methods will target two questions. (i) Proﬁling: What organisms\n14 constitute a given sample? (ii) Association: How are samples different in their organismal composition, and\n15 how do these differences connect to measurable characteristics of their environment? While both questions\n16 have been subject to considerable research, many computational challenges remain, providing an opportunity\n17 for better methods to make a signiﬁcant impact. Instead of focusing solely on new algorithms, the lab will\n18 also work on building better reference datasets and combining data from multiple sources. Thus, the project\n19 aims to harness the unprecedented computational power, large available datasets, and recent advances in\n20 machine learning to improve state-of-the-art dramatically. The project will not use off-the-shelf machine learning\n21 methods in a black-box fashion. Instead, it develops methods that incorporate biological knowledge (e.g., of the\n22 evolutionary relationships) into machine learning methods in a principled biologically-motivated fashion.\n23 The lab will pursue several ambitious goals for both proﬁling and association questions. The project will\n24 (i) create methods to infer a continuously-updated reference alignment and tree encompassing all sequenced\n25 prokaryotic genomes (half a million currently) to be used for proﬁling, (ii) build methods for ultra-sensitive sam-\n26 ple proﬁling, (iii) use deep learning to connect data obtained using amplicon sequencing and metagenomics,\n27 (iv) build discordance-aware phylogenetic measures of sample differentiation, and (v) develop machine learning\n28 methods for associating a proﬁled microbiome to phenotypes of interest such as disease. These new methods\n29 will draw on statistics, machine learning, discrete optimization, and high-performance computing. Consistent\n30 with the goals of MIRA, the project may explore new unforeseen opportunities if they ﬁt its general goals.",
      "project_tags": "SCHOOLS OF ARTS AND SCIENCES",
      "start_date": "2025-11-13",
      "end_date": null,
      "external_id": "5R35GM142725-05"
    },
    {
      "project_title": "Machine Learning Methods to Predict Cancer Progression and Estimate Treatment Effectiveness",
      "project_description": "Project Summary\nCancer is a leading cause of death worldwide. In the past few years, an average of around 18.1 million new\ncases of cancer (per year) were diagnosed. Physicians often decide which treatment to give a patient with the\ngoals of prolonging overall survival, preventing recurrence, and minimizing complications. Generally,\nRandomized Controlled Trials (RCTs) are used to determine the efficacy of one therapy versus another therapy\nbut are untenable in many situations due to ethical and financial constraints. Recent work has leveraged\nobservational data to develop machine learning models that capture the progression of chronic diseases such\nas Cystic Fibrosis and Parkinson’s. However, using machine learning to determine treatment efficacy and\npredict important clinical endpoints, such as overall survival (OS) or progression free survival (PFS), in cancer\nhas not been well studied. This gap in knowledge is due to a lack of benchmark cancer datasets, limited\nsample sizes for rare cancers, and challenges specific to cancer management, such as tumor heterogeneity\nwithin patients leading to differential treatment response. In spite of these challenges, recent methodological\nimprovements in machine learning, such as the use of inductive biases and auxiliary data to improve prediction\nin data-scarce settings as well as improved treatment effect estimation methods, present an opportunity to test\nthe promise of machine learning in the cancer setting. Therefore, the overarching goal of the proposed\nwork is to develop methods that will enable training of machine learning models that capture the signal\nin longitudinal, observational cancer data and ultimately improve prediction of clinical endpoints as\nwell as estimation of cancer treatment effects. As a case study and evaluation bed for my development of\nthese methods, I will focus on multiple myeloma, an incurable plasma cell cancer. Aim 1 of this proposal will\nfocus on improving prediction of survival endpoints and depth of treatment response. I will train a latent\nvariable model with a novel learning algorithm that will leverage auxiliary longitudinal data to improve the\npower of the model, enabling better prediction of clinical endpoints. Aim 2 will tackle the related, yet distinct,\nquestion of treatment effect estimation, particularly with respect to different combination chemotherapies.\nMeta-learner models will be used to estimate average and conditional average treatment effects. A sensitivity\nanalysis framework with clinically-interpretable sensitive parameters will be used to assess reliability of the\nestimates. Finally, aim 3 will provide a machine learning decision support tool to augment physician decision\nmaking in cancer management. A user study will be conducted with the tool to determine if it improves\nphysician assessment of patients. This proposal provides a general methodological framework that can be\napplied to any cancer dataset and improves understanding of how to effectively use machine learning models\ntrained on observational data to improve care of cancer patients.",
      "project_tags": "SCHOOLS OF MEDICINE",
      "start_date": "2025-11-13",
      "end_date": null,
      "external_id": "5F30CA268631-04"
    },
    {
      "project_title": "Forecasting emotional disorder symptoms: A dynamical systems and time-series machine learning approach",
      "project_description": "PROJECT SUMMARY\nEmotional disorders are among the primary causes of disability and impairment worldwide. Predicting their future\ncourse can be used to improve disease management and to deliver more timely and individually tailored\ntreatment. However, accurate forecasting is notoriously difficult. A major challenge is that the static features\ntraditionally used for prediction (i.e., cross-sectional symptom data) are not theoretically optimal for forecasting\ndisease progression. Overwhelming evidence demonstrates that emotional disorders are characterized by\nbehaviors that unfold dynamically over time. A more principled disorder conceptualization is needed that\nemphasizes dynamic time-series features of emotional psychopathology. To address this gap, dynamical\nsystems and complex network theory have been proposed as theoretical models that can explain the dynamic\nbehavior of emotional disorders. In the current proposal, we will create a precision-medicine framework for\npredicting emotional disorder symptoms that leverages theoretically relevant time-series measures using\nmodern “forecasting” machine learning methods. Patients with emotional disorders will be recruited to undergo\na 4-week ecological momentary assessment period during which symptom and affect data will be collected 5\ntimes per day and passive sensor data will be continuously monitored. Aim 1 will evaluate the predictive utility of\n“forecasting” machine learning using EMA-based dynamical systems and network features in predicting future\ntransdiagnostic symptom domains. Aim 2 will evaluate the added predictive utility of incorporating dynamic time-\nseries features from passive sensor data alongside EMA data in predicting future transdiagnostic symptom\ndomains. In Aim 3, we will develop dynamic time-series phenotypes of emotional disorders using both self-\nreported EMA and sensor data. The current proposal will result in the first forecasting machine learning\nframework designed to leverage temporally dynamic features for predicting the future course of symptoms,\nthereby better capturing the dynamic nature of emotional psychopathology. This is significant as it facilitates\nmore accurate monitoring and just-in-time interventions for emotional disorders, alleviating one of the major\ncauses of disease and burden worldwide. Furthermore, a tailored training plan was created to cultivate\ncompetencies in advanced time-series computational techniques and career development, including expertise\nin (1) early warning signals in dynamical systems and network theory, (2) time-series machine learning\n(forecasting), (3) unsupervised machine learning, (4) passive sensor data, and (5) grantsmanship and transition\nto academic independence, with guidance from Dr. Paola Pedrelli (primary mentor), Dr. Richard McNally (co-\nmentor), Dr. Jordan Smoller (co-mentor), and Drs. Rosalind Picard and Amanda Baker (consultants). Research\nand training activities will harness the exceptional resources at Massachusetts General Hospital/Harvard Medical\nSchool. This training plan will facilitate a future research program leveraging computational modeling to advance\nprecision medicine and personalized care for emotional disorders.",
      "project_tags": "SCH ALLIED HEALTH PROFESSIONS",
      "start_date": "2025-11-13",
      "end_date": null,
      "external_id": "5K23MH132896-02"
    },
    {
      "project_title": "Analyze: Machine Learning for Mobility Data",
      "project_description": "Limited mobility due to conditions like osteoarthritis (OA), cerebral palsy, and Parkinson’s disease affects\nmillions of individuals, at enormous personal and societal cost. Rehabilitation can dramatically improve mobility\nand function, but current rehabilitation practice requires in-person guidance by a skilled clinician, increasing\nexpense and limiting access. Mobile sensing technologies are now ubiquitous and have the potential to\nmeasure patient function and guide treatment outside the clinic, but they currently fail to capture the\ncharacteristics of motion required to accurately monitor function and customize treatment. Millions of low-cost\nmobile sensors are generating terabytes of data that could be analyzed in combination with other data, such as\nimages, clinical records, and video, to enable studies of unprecedented scale, but machine learning models for\nanalyzing these large-scale, heterogeneous, time-varying data are lacking.\n To address these challenges, we will establish a Biomedical Technology Resource Center —The Mobilize\nCenter. Through the leadership of an experienced scientific team, we will create and disseminate innovative\ntools to quantify movement biomechanics with mobile sensors.\n Specifically, we will:\n 1. Push the bounds of what we can measure via wearable sensors using models that compute muscle\n and joint forces and metabolic cost of locomotion. These models, based on biomechanical and machine\n learning models, will be disseminated via our newly created OpenSense software, which will be used\n by thousands of researchers to gain new insights into patient biomechanics using mobile sensors.\n 2. Meet the need for tools that analyze data about movement dynamics and develop machine learning\n models to analyze and generate insights from unstructured, high-dimensional data, including time-\n series (e.g., from mobile sensors), images (e.g., MRI), and video (e.g., smartphone video of a patient’s\ngait).\n 3. Provide tools needed to intervene in the real-world. We will develop algorithms to accurately quantify\n kinematics outside the lab for long durations using data from inertial measurement units (IMUs). We will\n also build behavioral models to adapt and personalize goal setting, drawing on movement records from\n 6 million individuals, as well as health goals and exercise for 1.7 million people.\n Through intensive interactions with our Collaborative Projects, we will focus on improving rehabilitation\noutcomes for individuals with limited mobility due to osteoarthritis, obesity, Parkinson’s disease, and cerebral\npalsy. The Center’s tools and services will enable researchers to revolutionize how we diagnose, monitor, and\ntreat mobility disorders, providing tools needed to deliver precision rehabilitation at low cost and on a massive\nscale in the future.",
      "project_tags": "Domestic Higher Education",
      "start_date": "2025-11-13",
      "end_date": null,
      "external_id": "5P41EB027060-05"
    },
    {
      "project_title": "Machine learning of biomolecular interactions and the human signaling networks they comprise",
      "project_description": "My lab will use machine learning to build physically-grounded models of biomolecules and their interactions and\napply these models at proteome (genome) scale to address basic questions in the systems biology of human\nsignaling. On the modeling front, our efforts will focus on building computational models of protein-ligand\ninteractions, with a specific emphasis on post-translationally modified ligands that cells widely employ in signaling\nnetworks. I hypothesize that a step change in accuracy and generality of protein-ligand interaction models is\npossible using deep learning advances in protein structure prediction and protein representation learning. My\nlab has been at the forefront of these advances, having developed the first end-to-end differentiable model of\nprotein structure prediction (RGN); the first protein language model (UniRep), a key technique for learning\nmathematical representations that capture chemical, structural, and evolutionary properties of proteins; and one\nof the first deep learning methods for protein-protein interactions (HSM). We will leverage our expertise in these\ndomains to predict protein-ligand interactions based on both sequence and structure information. We will further\ndevelop specialized models for predicting protein structures and alternate protein conformations for the purpose\nof predicting protein-ligand interaction, using these predictions as inputs for our protein-ligand interaction models.\nOn the biological front, we will employ these machine-learned models to assemble person-specific signaling\nnetworks to understand how normal allelic variation is manifested at the level of signaling networks, and how\nthese networks are perturbed in human diseases. To study general variation in signaling networks, we will use\nexome sequences (UK Biobank and NHLBI TOPMed) to build individualized networks that map person-specific\nprotein sequences to protein-ligand affinities. We will quantify how network topology varies among individuals\nand populations and test whether disease-associated traits correlate with topology. We will also compare\nnetworks of healthy and disease-afflicted persons to identify topological differences that predispose individuals\nto genetic diseases. Ultimately, I expect machine-learned models to be sufficiently predictive of ligand binding\nthat mechanistic understanding of pathway rewiring by mutations is possible. While my focus will be\ncomputational, I expect to carry out close collaborations—with the Fordyce Lab (Stanford) to experimentally\ncharacterize and validate protein-ligand interactions and the Shen Lab (Columbia) to perform statistical genetic\nanalyses—to exploit synergies at the interface of computation and experimentation.",
      "project_tags": "SCHOOLS OF MEDICINE",
      "start_date": "2025-11-13",
      "end_date": null,
      "external_id": "5R35GM150546-03"
    },
    {
      "project_title": "Knowledge-guided automated machine learning methods for modeling the interaction of HIV with addictive drugs",
      "project_description": "The primary goal of this project is to bring powerful data mining and analytics methods, as well as computing\ntechnology and technical software, to the substance abuse and HIV research communities to enable everyone,\nregardless of expertise, to model multimodal data for the purpose of disease prediction with the end goal of\nclinical decision support. Our working hypothesis is that automated machine learning (AutoML) will accelerate\nthe development of innovative strategies for translation of research findings to clinical use by enabling everyone\nto analyze biomedical data using data mining methods. This project builds on our user-friendly and open-source\nTree-Based Pipeline Optimization (TPOT) platform that represents one of the very first and most widely used\nopen-source AutoML methods. A major benefit of this approach is that it makes machine learning accessible to\nnovice users because it takes the guesswork and complexity out of picking, running, tuning, and optimizing\nmachine learning algorithms and the various pre- and post-processing methods. Bringing this technology to the\nclinical and translational research communities will open the door to broad adoption of data mining methods for\nembracing the complexity of the relationship between multimodal substance abuse biomarkers and clinical\noutcomes such as HIV progression and severity. We propose here novel algorithms to adapt and extend TPOT\nfor the large volumes of clinical data that are being collected on patients infected with HIV at Cedars-Sinai\nMedical Center in Los Angeles. Specifically, we will first develop an ontology-based Addiction KnowledgeBase\n(AddictionKB) tailored to HIV endpoints and clinical data derived from electronic health records (EHRs) and their\nrelationships with HIV infection and outcomes to inform the machine learning algorithms and assist with\ninterpretation (AIM 1). We will then develop a large language model (AddictionLLM) using Bloom to allow for\nnatural language queries of AddictionKB to perform knowledge-guided feature selection (AIM 2). We will extend\nour TPOT AutoML (AddictionML) to include special operators to call the AddictionLLM algorithm for automated\nknowledge-guided feature selection within machine learning pipelines (AIM 3). We will apply AddictionKB,\nAddictionLLM, and AddictionML to the identification of substance abuse disorders and other clinical measures\nthat are predictive of HIV progression and severity (AIM 4). Finally, we will distribute and support AddictionKB,\nAddictionLLM, and AddictionML as open-source software (AIM 5).",
      "project_tags": "Independent Hospitals",
      "start_date": "2025-11-13",
      "end_date": null,
      "external_id": "5R01LM014572-02"
    },
    {
      "project_title": "Machine-Learning Models for big data omics",
      "project_description": "Project Abstract/Summary\nMore than 75% of the data generated from mass spectrometry (MS) - based omics experiments are wasted due to\ninefficiency of existing algorithmic methods that deduce peptides. The peptides that do get identified by existing\ncomputational methods usually come from abundant proteins – and hence recent calls by scientists to study\noverlooked proteins are gaining traction. These non-abundant and overlooked proteins might have the same (or\nmore) importance in human systems biology health, and disease. Yet, all downstream analysis and conclusions –\nrelated to human health – are based on suboptimal and incomplete peptide deductions indicating formal investigation\nis warranted and urgently needed. In the recent decade, advances in machine-learning (ML) models have provided\na critical step and have made it possible to develop more accurate and deeper pipelines for MS data analysis. Our\npreliminary work and experiments suggest that the limited training search-space exhibited by labelled spectral libraries\nmakes robustness, and generalizability of existing ML models highly susceptible and may not effectively work for real-\nworld data. The overall objective of my research lab using this MIRA mechanism is to design and develop robust,\nreliable, and generalizable machine-learning models for peptide deduction from MS data from omics experiments.\nOur proposed work fills four key knowledge gaps in development of ML models pursued via this MIRA grant that, if\nfilled, will lead to superior computational techniques capable of inferring both abundant and non-abundant peptides.\nOur general strategy will involve design and development of generative models, self-learning models, biologically\ninspired models, and methods to infer uncertainty quantification. In addition, we will strive to focus on two key gaps in\nadaptation of ML models that will be filled via developing ML-ready workflows and developing easy-to-use software\ninfrastructure that can be used by scientists. All this effort via MIRA grant mechanism will fill a critical gap in our\nunderstanding and ability to deduce peptide (that are novel) and will contribute a fundamental tool for studying complex\ncommunities in proteomics, and meta-proteomics data. At the end of this grant funding cycle, it is our expectation that\nwe will have designed and developed highly accurate ML peptide deduction engine capable of end-to-end analysis of\nthe MS based omics data– that is robust, generalizable, and more accurate than their algorithmic counterpart. Our\nproposed work will facilitate reproducibility by developing ML models that perform well – irrespective of underlying MS\ndata quality or completeness – will be a highly impactful outcome. This proposed work will also serve as the\nfoundation for analysis of more complex data sets related to meta-proteomics, and proteogenomics as one of our\nlong-term goals that we hope to achieve using this MIRA grant mechanism.",
      "project_tags": "BIOMED ENGR/COL ENGR/ENGR STA",
      "start_date": "2025-11-13",
      "end_date": null,
      "external_id": "5R35GM153434-02"
    },
    {
      "project_title": "Machine learning approaches to predict Acetylcholinesterase inhibition and model applications",
      "project_description": "Summary\nOrganophosphorus (OP) compounds are one of the most common causes of poisoning worldwide. There are\nnearly 3 million poisonings per year resulting in three hundred thousand deaths. OPs bind to acetylcholinesterase\n(AChE), rendering the enzyme incapable of hydrolyzing acetylcholine (ACh) in the cholinergic synapses and\nneuromuscular junctions. Subsequent accumulation of ACh leads to overstimulation of the affected neurons\nacting through muscarinic and nicotinic receptors. Some of the adverse effects of pesticides on non-target\norganisms such as fish, amphibians and humans have also occurred as a result of biomagnifications of the toxic\ncompounds. Since AChE is a very well-studied target, the likelihood of finding further new inhibitors amongst\nwell-known drugs and molecules is likely unlikely and therefore we need to look further afield and do this in a\nmore efficient manner. Computational approaches such as machine learning are an approach that can be used\nto learn from diverse literature to enable virtual screening. Following our preliminary work generating Bayesian\nmodels for human AChE we have performed a high throughput screen of 2431 compounds and identified 66\ncompounds that were “active” against eel AChE. We recently completed a phase I SBIR in which we expanded\nthe use of these machine learning models to curate additional AChE data, built and validated AChE models with\nmany algorithms in parallel and used them to identify AChE inhibitors from various species to predict OP induced\npoisoning and possible threats to the environment. In addition, we have recently curated further literature data\nand generated models for the closely related enzyme BChE using a contrastive learning algorithm approach to\nscore a library of 5 million molecules from various vendors in order to select molecules for testing and have\nidentified several novel selective inhibitors. In Phase II we will develop the MegaAChE software product further\nfor prediction of AChE inhibition and incorporate uncertainly prediction features and new algorithms such as\nlarge language models. We will also use this software to design and develop AChE reactivators that could\nprovide a new treatment for OP pesticide and nerve agent exposure. We now propose the following aims to\nfurther develop and validate the MegaAChE software as a commercial product:\nAim 1: Modeling uncertainty in AChE models\nAim 2: Large language models for AChE and BChE datasets\nAim 3: Develop new reactivators to treat AChE poisoning using generative design\nOur ultimate goal will be to provide software and models to predict AChE inhibition which will be a commercial\nproduct. In addition we will develop new molecule intellectual property which we can then license to a larger\ncompany. Computational models for AChE therefore have beneficial dual-use potential both for identifying\nmolecules that could have environmental or human toxicity, while alternatively such machine learning models\ncould also help us identify molecules with therapeutic utility for Alzheimer’s disease or as treatments for\npoisoning.",
      "project_tags": "Domestic For-Profits",
      "start_date": "2025-11-13",
      "end_date": null,
      "external_id": "5R44ES033855-03"
    },
    {
      "project_title": "Development of Dynamic Resting State Functional Connectivity Machine Learning Framework for Dementia",
      "project_description": "Project Summary/Abstract\nThe objective of this proposal is to provide a robust course of training for Fei Jiang, Ph.D., a candidate with\nan excellent foundation in statistical and machine learning research, to enable her to become an independent\ninvestigator in the ﬁeld of quantitative data analysis and statistical/machine learning methods development for\nneuroimaging research. The proposed research aims to extract dynamic resting-state functional connectivity\nfrom multimodality imaging and use them for the prediction of cognitive decline. The central hypothesis is that\nthe resting state functional connectivity changes over the imaging acquisition period, and this dynamic pattern is\ncrucial for the optimal prediction of cognitive decline. Towards proving this hypothesis, a unique machine learn-\ning framework is proposed to (1) robustly extract dynamic resting-state functional connectivity from multimodality\nimaging; (2) identify the important features that are associated with individuals' cognitive scores; and (3) predict\ncognitive decline using the identiﬁed important features. Successful completion of the proposed research will\nprovide the next generation machine learning framework for the extraction and analysis of dynamic resting-state\nfunctional connectivity and lead to potential endpoints that can be used in the assessment of treatment effects.\nRecognizing the multidisciplinary nature of the work proposed, the author will be mentored and work closely with\nan expert committee from multiple scientiﬁc areas of relevance to the project (Neuroimaging, Neurodegenerative\ndisease, Biostatistics): Srikantan Nagarajan (primary mentor), Ph.D., Department of Radiology and Biomedical\nImaging, Ashish Raj (co-mentor), Ph.D., Department Radiology and Biomedical Imaging, William W. Seeley (ad-\nvisor), M.D., Ph.D., Department of Neurology, John Kornak (advisor), Ph.D., Department of Epidemiology and\nBiostatistics, Marilu Gorno Tempini (collaborator), M.D., Ph.D., Department of Neurology, Charles McCulloch\n(collaborator), Ph.D., Department of Epidemiology and Biostatistics. This committee will be coordinated by Dr.\nNagarajan. The goal is that by the end of the K25, Dr. Jiang will have the requisite knowledge, technical skills,\nand expertise to submit a successful R01 proposal that integrates her expertise in statistical and machine learn-\ning methods with a knowledge of the questions and approaches pertaining to imaging in neuroscience, acquired\nthrough this training period.",
      "project_tags": "SCHOOLS OF MEDICINE",
      "start_date": "2025-11-13",
      "end_date": null,
      "external_id": "5K25AG071840-04"
    },
    {
      "project_title": "SCH: Machine learning for personalized preventative intervention in perinatal depression",
      "project_description": "PROJECT SUMMARY (See instructions}:\nThe goal for this project is to develop machine learning (ML) to accelerate the discovery of scalable,\ninterpretable, and personalized preventative interventions for perinatal depression. Approximately 15% of\npregnant individuals experience perinatal depression, which can have devastating long-term\nconsequences. Suicide is a leading cause of death among new mothers in the U.S. However,\nindividualized preventive interventions are not routinely offered at present due to lack of routine screening\npractices and limited resources. Machine learning offers an opportunity to improve mental health services\nduring the perinatal period by identifying patients who would benefit from specific preventative\ninterventions. We will develop fundamental advances in ML techniques for the discovery of personalized\ninterventions as well as advances in the social science of incorporating domain and lived experience into\nalgorithmic systems. Our specific aims bridge prediction with the adaptive experimentation needed to\nidentify personalized interventions. In Aim 1, we will develop methods which use existing historical data to\nlay the groundwork for a randomized experiment of interventions, including to robustly inform which\nvariables to measure and how to set an initial allocation policy based on those variables. In Aim 2, we will\nelicit domain expertise from clinicians and lived experience expertise from perinatal individuals via semistructured\ninterviews which will inform both the requirements for a trustworthy and implementable ML\nsystem and a structured representation of clinical expertise that can be incorporated to initialize a ML policy\ntogether with historical data. Finally, in Aim 3, we will synthesize these products into an integrated\nframework for online learning to discover personalized preventative interventions. The key component of\nthis framework is continued interaction with patients to provide intermediate feedback and accelerate\nconvergence to a high-quality policy for allocating preventative interventions.",
      "project_tags": "SCHOOLS OF ARTS AND SCIENCES",
      "start_date": "2025-11-13",
      "end_date": null,
      "external_id": "5R01MH139097-02"
    },
    {
      "project_title": "Analytics, BioStatistics, and Machine Learning Module",
      "project_description": "SUMMARY – ANALYTICS, BIOSTATISTICS, AND MACHINE LEARNING MODULE\nThe Analytics, Biostatistics, and Machine Learning (ABML) module integrates expertise in the Departments of\nOphthalmology, Pediatrics, and Biostatics in an innovative approach to create access to modern computational\nanalysis of integrated datasets. Our participating faculty generate a tremendous amount of data from a variety\nof sources, including de-identified medical records, retinal imaging, tissue imaging, physiological recordings\nfrom members of our cortical vision faculty, performance-based tests, molecular data from metabolomics,\nmicrobiome, RNA-Seq, ATAC-Seq, single-cell/nuclei RNA- and ATAC-Seq, and ChIP-Seq. The ABML module\nwill connect people generating data with module personnel who are experts in biostatistics, statistical\nmodeling, machine learning, and deep learning methodologies. The overall goal is to provide high-level\nanalytical guidance, accelerate and enhance research discovery, and promote new collaborations between\ndata-generating and analytical scientists. Modular activities will also be available for the training of our students\nand postdocs and increasing synergistic interactions between the P30 participating faculty.",
      "project_tags": "Domestic Higher Education",
      "start_date": "2025-11-13",
      "end_date": null,
      "external_id": "5P30EY008098-37"
    },
    {
      "project_title": "Reproducibility statistics and machine learning methods for systematic phenotyping and model integration across animals, organs, and technologies",
      "project_description": "Project Summary/Abstract\nModern high throughput biomedical research is collecting an ever-increasing number of variables spanning different\nphysical scales, systems, and species. In this era of “multi-omics”, multiple data sets are often collected on the same\nanimal, spanning modalities that may variously include genomics, transcriptomics, proteomics, epigenomics,\nmetabolomics, connectomics, and other “omics” domains, with each individual omics data set consisting of hundreds up\nto hundreds of thousands of variables. These exciting developments in data acquisition have led animal model researchers\ninto a new data paradigm, with many labs now relying on machine learning methods for dimensionality reduction,\nclustering, phenotyping, data integration, and similar techniques assembled into pipelines as part of standard practice.\nFrequently in this scenario, the number of variables collected p (e.g., metabolites) becomes as large as (or larger than) the\nnumber of observations n (e.g., mice). In statistics, this is referred to the Large Dimensional Limit (LDL) regime2.\n This dramatic increase in the number of variables relative to observations changes the statistical behavior of the\ndata, leading to significant problems with machine learning model fitting behavior that are not widely appreciated outside\ncertain domains of mathematical statistics and physics. Estimates that should fundamentally describe the structure of data,\nsuch as the principal components, no longer converge to their true underlying values (as they do in the classical “small\ndata” case when p is much smaller than n). Further, similar failures extend far beyond principal components impacting\nmany other widely used machine learning approaches, and multi-stage analysis pipelines and complex animal data\ndistributions further compound these problems, collectively resulting in a modern reproducibility crisis in animal research.\n Here we show that these issues also broadly impact the test-retest reproducibility of machine learning methods on\nheld out data, with reproducibility on new data following a “universal reproducibility curve” in which performance\nchanges rapidly from non-reproducible to reproducible as a function of sample size and number of variables. A direct\nconsequence of this phase transition is that modern animal model research studies are subject to a reproducibility\ntransition such that below a certain value p/n machine learning algorithms fail to yield reproducible results. Furthermore,\nfor ratios of p/n above this value, collecting additional data will yield rapidly diminishing marginal returns in\nreproducibility that may not be justified by data acquisition costs or trade-offs. Together these phenomena define what we\ncall “universal reproducibility curves” that depends on the “aspect ratio” p/n of the data (as well as the strength of the\nmultivariate biological signal that the data contain). Gaining a mechanistic understanding of such curves will allow us to\nsystematically solve important open problems in machine learning such as how to measure reproducibility across machine\nlearning methods and pipelines, how many data samples to collect and how many variables to measure to ensure\nreproducibility, when to stop collecting data, and how to design better embedding algorithms for data integration and\nsystematic phenotyping in real-world animal research models.",
      "project_tags": "SCHOOLS OF MEDICINE",
      "start_date": "2025-11-13",
      "end_date": null,
      "external_id": "1R01OD039830-01"
    },
    {
      "project_title": "Trustworthy Machine Learning for Clinical Diagnosis and Decision Support",
      "project_description": "ABSTRACT\nInfectious diseases, such as pulmonary tuberculosis and sepsis, are associated with significant patient morbidity and mortality. Because of their public health significance, recent research in artificial intelligence (AI) and machine learning (ML) have explored how deep learning models may be used as clinical decision support tools to work alongside clinicians in improving patient care. However, it is well-documented that AI algorithms—even those approved by the Food and Drug Administration (FDA)—are inaccurate and perform poorly on real-world patients, especially those that are not made sufficiently available during model development. As a result, such tools often inadvertently lack consistency and reliability due to their poor performance on different patient populations. Especially in high-stakes applications such as healthcare where there is a small margin for error, it is important to train neural networks that are clinically interpretable, trustworthy, and reliable for all patient populations. The reasons behind inconsistent model performance are complex, but can be largely distilled into two major algorithmic limitations: (1) traditional ML predictive models may not be well-calibrated with true clinical decision-making used by physicians; and (2) publicly available model training datasets may lack the natural variation in patient disease presentation necessary to ensure generalizable model performance. In this work, I propose a series of algorithmic and practical innovations to address these two algorithmic limitations in the clinical diagnosis and management of pulmonary tuberculosis and sepsis. I will accomplish this task by increasing the robustness and reliability of AI models in healthcare settings. Firstly, in order to better align predictive models with clinical reasoning for the diagnosis of pulmonary tuberculosis, I will show how publicly available vision-language foundational models can be used to improve the diagnostic accuracy of clinicians in resource-limited hospital settings (Aim 1). Secondly, I will propose and validate a novel computational algorithm that leverages historical aggregate patient data to improve the reliability of clinical decision support systems for sepsis treatment (Aim 2). These experiments will collectively demonstrate how AI algorithms can be better leveraged for various applications spanning multiple domains of patient care. In providing solutions for these clinically relevant problems, I will further develop the technical skills and scientific reasoning needed as a future radiologist and academic researcher in machine learning. I look forward to leveraging both my graduate education and clinical training together to ultimately become a well-rounded physician-scientist and independent investigator.",
      "project_tags": "SCHOOLS OF MEDICINE",
      "start_date": "2025-11-13",
      "end_date": null,
      "external_id": "5F30MD020264-02"
    },
    {
      "project_title": "Personalized Postpartum Hemorrhage Prediction Using Machine Learning And Polygenic Risk Scores",
      "project_description": "Postpartum hemorrhage, defined as estimated blood loss of at least 1000 mL within 24 hours of delivery, is the leading cause of severe maternal morbidity and mortality. Annually, postpartum hemorrhage complicates 2-3% of all pregnancies and accounts for 140,000 maternal deaths globally. While clinical postpartum hemorrhage risk prediction tools have been developed, they fail to identify up to 40% of cases; as a result, no evidence-based prediction tool is currently widely adopted in clinical practice. Thus, an efficient, precise, and personalized postpartum hemorrhage risk prediction tool is urgently needed.\nRecently, machine learning approaches have been increasingly used to develop accurate predictive models with superior performance compared to traditional statistical approaches and to discover new predictors, with little prior pre-specification. Moreover, the explainable machine learning methods allow for transparent decision-making and ensure model generalizability. In this way, machine learning models may lead to more accurate postpartum hemorrhage prediction than currently existing tools. In addition, since up to 18% of postpartum hemorrhage risk is familial and many of the clinical risk factors associated with postpartum hemorrhage have a well-established polygenic architecture, using polygenic risk tools may further enhance postpartum hemorrhage risk prediction. In line with the NIH IMPROVE initiative goals to improve maternal safety and outcomes, we propose here to develop a high-fidelity algorithm, combining both clinical and genetic factors, to more accurately predict the risk of postpartum hemorrhage in pregnant individuals. We will leverage our rich patient database and state-of-the-art computational tools to: (1) develop an improved algorithm to stratify patient postpartum hemorrhage risk with a focus on transparency and high performance, and (2) delineate the contribution of genetics to postpartum hemorrhage risk. Overall, this project will advance our ability to precisely predict patients at risk for postpartum hemorrhage, with the investigation of novel predictors, interaction between clinical and genetic contributors, and novel application of both machine learning and polygenic risk scores to these outcomes. Ultimately, we aim to validate and implement these tools in clinical practice, leading to a greatly enhanced ability to prevent maternal morbidity and mortality. By completion of these aims, I will develop a specific skill set essential for establishing my research trajectory and transition to independence as a physician-scientist utilizing translational computational approaches to predict and improve adverse obstetric outcomes.",
      "project_tags": "Independent Hospitals",
      "start_date": "2025-11-13",
      "end_date": null,
      "external_id": "5K08HL161326-04"
    },
    {
      "project_title": "Supporting IGVF by modeling genetics, function, and phenotype with machine learning",
      "project_description": "PROJECT SUMMARY\nLeveraging the power of the human genome to understand the risks, causes, and treatments of human dis-\nease remains a grand challenge for all of biology and medicine. While sequencing costs have plummeted, and\nclinical implementation has become commonplace, interpreting human genomes remains a highly challenging\ntask. It is our hypothesis that understanding the function of the genome and its products at a molecular, tissue,\nand phenotypic level using advanced machine learning will help unlock the door to better interpretation for sci-\nentific discovery and better clinical outcomes based on genomic medicine. To that end, our team has spent\nthe past two decades working to develop computational models of biology, to predict how those models are\nperturbed through changes in the genome, and to use those perturbations to model phenotype and disease.\nWe have had many research outputs in this area, having developed and published a number of widely used\nmethods that predict biochemical and phenotypic changes caused by genetic variants to infer phenotype and\npathogenicity. However, we believe that there is a coming convergence between the variability in clinical inter-\npretation, high-throughput biotechnology assays, and modern machine learning methodology that will result in\nmore accurate clinical assessments and improved clinical care. Therefore, in this ambitious proposal, we are\naddressing important questions in variant and genome interpretation consistent with this view and the mission\nof the IGVF Consortium. Our major goals include (1) developing advanced semi-supervised approaches to\npredict variants that disrupt molecular function and/or are capable of altering phenotypes; (2) identifying in-\nformative assays, variants, and genes to automate experimental design with an emphasis on resource alloca-\ntion and reduction of ascertainment bias in the Consortium; and (3) developing machine learning approaches\nto integrate these models into a workflow of the IGVF Consortium and enable the interaction between compu-\ntation and experiment in order to catalyze advances in both genetic variant interpretation and predictive model\ndevelopment.",
      "project_tags": "SCHOOLS OF ARTS AND SCIENCES",
      "start_date": "2025-11-13",
      "end_date": null,
      "external_id": "5U01HG012022-05"
    },
    {
      "project_title": "Machine learning to predict cure in severe pneumonia episodes",
      "project_description": "PROJECT ABSTRACT\nPneumonia is the most common cause of death due to infection worldwide and in patients admitted to the\nintensive care unit (ICU). Some patients are successfully cured with a short course of antibiotics, but over a third\nare not readily cured despite appropriate therapy and have worse outcomes. Current ICU prediction models\nfocus on remote outcomes, such as hospital mortality, and are not built to predict short term outcomes of\npneumonia episodes. These episodes evolve over days, which are the timeframe during which clinical\ninterventions can shift patient trajectories toward favorable outcomes. I developed a machine learning approach\ncalled CarpeDiem based on the practice of daily physician rounds to disentangle the contributions of unresolving\npneumonia to poor outcomes in patients with respiratory failure. These data suggest identifying patients likely to\nfail pneumonia treatment early in their clinical course could impact ICU outcomes.\nIn this proposal, I will build upon my previous CarpeDiem methodology to develop and validate a machine\nlearning model to predict whether a pneumonia episode will be cured on day 7 using features from days 1-3. I\nwill leverage the data from the Successful Clinical Response in Pneumonia Therapy (SCRIPT) U19 Systems\nBiology Center, a one-of-a-kind biorepository that includes over 700 patients and 1,400 bronchoalveolar lavages.\nI will use both clinical electronic health record data and single-cell RNA sequencing transcriptomic data in my\nmodels. My predictions and hypotheses are founded on causal biologic studies in murine models of lung injury\ndemonstrating the importance of regulatory T cells to promote pneumonia resolution. This proposal will give me\ntraining in deep learning methods, deployment of machine learning models, and computational skills to analyze\nhigh-dimensional single-cell transcriptomic data.\nMy project addresses critically important gaps in current modeling and predictors of pneumonia outcome and\nwill overcome current limitations in machine learning approaches to ICU data. I am supported by my mentors\nRichard Wunderink, a world-renowned expert in pneumonia and critical care. My co-mentor Benjamin Singer\nprovides lung immunology expertise, and my co-mentor Yuan Luo provides expertise in machine learning. My\nResearch Advisory Committee includes experienced scientists in computational transcriptomics, electronic\nhealth record modeling, database informatics, and lung immunology. My training plan leverages the unique\nresearch environment at Northwestern University to grow my substantial track record while expanding my skills\nin electronic health record and genomic data to support my academic development as a future R01 funded\ninvestigator. Identifying early features of treatment failure provides targets for intervention, prompting additional\ndiagnostics, such as repeat bronchoalveolar lavage or imaging, or treatment modifications. Recognition of early\ntreatment failure offers the opportunity to divert a patient’s downward trajectory toward cure in critically ill patients.",
      "project_tags": "SCHOOLS OF MEDICINE",
      "start_date": "2025-11-13",
      "end_date": null,
      "external_id": "5K23HL169815-02"
    },
    {
      "project_title": "Advanced machine learning models to integrate multi-modal biomedical datasets for gene regulation and precision medicine",
      "project_description": "Vast amounts of multi-modal biomedical datasets have become available due to advances in high-throughput biomedical technologies. Each of these distinct data modalities such as genomics, epigenomics, and transcriptomics (collectively called as “multi-omics”) offers complementary information about the underlying biology of living systems. Therefore, there is an urgent need for scalable methods capable of integrating multi-modal datasets across millions of individuals. Our research program is devoted to the development of open-source integrative computational tools designed to analyze high-dimensional multi-modal biomedical datasets such as multi-omics and electronic health records (EHR) data. In this MIRA renewal application, we aim to develop generalizable, biologically inspired, and interpretable machine learning solutions to address some of the key challenges present in the biomedical datasets such as data irregularities, dependencies between data modalities, and missing and noisy data. We will develop novel computational methods based on machine learning, deep learning, and graph representation learning to integrate multi-modal biomedical datasets to build generalizable and interpretable models. These models will be used for various prediction tasks such as predicting clinical outcomes, inferring regulatory networks, and identifying drugs that can be repurposed for other diseases. The vision of our research program is to develop open-source computational tools that efficiently integrate multi-modal biomedical datasets, enhancing our understanding of gene regulatory interactions and disease mechanisms. By leveraging machine learning, deep learning, graph representation learning, and foundational models, we aim to advance precision medicine, facilitating more informed treatment decisions.",
      "project_tags": "BIOMED ENGR/COL ENGR/ENGR STA",
      "start_date": "2025-11-13",
      "end_date": null,
      "external_id": "2R35GM133657-07"
    },
    {
      "project_title": "From protein structures to effective drugs via machine learning and molecular simulation",
      "project_description": "Project Summary\nRecent years have seen dramatic breakthroughs in methods for determining structures of proteins\nand other drug targets experimentally (e.g., cryo-EM) and predicting them computationally (e.g.,\nAlphaFold). These advances tremendously increase the potential of structure-based drug\ndiscovery, but going from an accurate target structure to an effective drug remains a difficult\nproblem. To do so, once must design molecules that bind tightly and selectively to the target,\nhave appropriate (drug-like) physiochemical properties, and exert a desired effect on the target’s\nfunction. This project will make advances in several areas critical to enabling the efficient\nstructure-based design of effective, safe drugs:\n1. Creation of machine learning methods to accurately predict a chemical compound’s\n binding affinity, drawing simultaneously on the target’s structure and experimentally\n determined affinities of other compounds that do or do not bind the target.\n2. Development of machine learning methods to design drug-like ligands that bind tightly and\n selectively, exploiting both generative artificial intelligence and iteration between\n computation and experiments.\n3. Determination of the mechanisms by which drugs can selectively stimulate or selectively\n block arrestin signaling at diverse GPCRs, achieving desired therapeutic effects without\n dangerous side effects.\nThis research builds on recent achievements of the Principal Investigator, Ron Dror, in two areas:\n(a) machine learning methods for structural biology, and (b) elucidation of the structural basis of\nGPCR signaling. It continues his record of collaborating with experimentalists to do innovative\ncomputational work with a strong impact on experimental biochemistry, structural biology,\npharmacology, and drug design.",
      "project_tags": "BIOMED ENGR/COL ENGR/ENGR STA",
      "start_date": "2025-11-13",
      "end_date": null,
      "external_id": "1R35GM158122-01"
    },
    {
      "project_title": "Metasurface enhanced and machine learning aided spectrochemical liquid biopsy",
      "project_description": "PROJECT SUMMARY\nLiquid biopsy modalities that can non-invasively detect disease-associated biomarkers from biofluids can enable\nearly cancer detection and patient monitoring with implications for improved survival rates. However, current\nmethods have not achieved critical sensitivity and accuracy to be approved for population screening programs.\nNew spectrochemical liquid biopsy methods, such as Raman and infrared spectroscopy, coupled with machine\nlearning models are emerging as next-generation diagnostic modalities. Yet, fundamental physical limitations of\nlight-matter interactions using conventional optical setups hinder the analytical performance of molecular\nspectroscopy techniques. Here, we propose to employ novel electromagnetic metasurfaces that can advance\nthe analytical sensitivity and chemical selectivity of infrared absorption spectroscopy enabling its real-world\napplications in the biomedical field. Moreover, our innovative laser-based spectral imaging approach can achieve\non-chip spectrometer-less chemical fingerprint retrieval eliminating clinically incompatible, complex, and bulky\ninstrumentation requirements.\nThe long-term goal of this project is to develop a rapid, label-free, portable, and non-invasive cancer detection\nplatform based on sensitive and accurate chemometric liquid biopsy and machine learning-aided discrimination\nmodalities. The overall objectives in this application are to (i) determine a potent metasurface design that can\nrobustly extract chemical fingerprint information from a complex biosample matrix, (ii) identify optimized design\nparameters for spectral imaging-based on-chip fingerprint retrieval (iii) establish measurement protocols and\ndata processing pipeline (iv) identify a machine learning model by which sensitive and accurate sample\ndiscrimination can be achieved. In the short term, we will pursue two specific aims: 1) develop novel engineered\nmetasurfaces for sensitive and specific spectrochemical biofluid analysis and demonstrate spectrometer-less\non-chip chemical fingerprinting 2) Test and validate the platform using biofluids from an ovarian cancer patient\ncohort and non-cancer controls. Our proposed approach is innovative because it catalyzes the state-of-the-art\nlaser-based infrared spectral imaging technology with powerful nanophotonic tools to enable its impact in\nbiomedical diagnostics and address an unmet medical need. In addition, the proposed interdisciplinary project\nis significant because it is expected to develop a non-invasive and accessible health screening platform that can\nultimately impact the clinical management of cancer and the survival outcomes equitably among diverse\npopulations.",
      "project_tags": "BIOMED ENGR/COL ENGR/ENGR STA",
      "start_date": "2025-11-13",
      "end_date": null,
      "external_id": "5R21EB034411-03"
    },
    {
      "project_title": "OpenMM: Scalable biomolecular modeling, simulation, and machine learning",
      "project_description": "PROJECT SUMMARY / ABSTRACT\nOpenMM is a widely used toolkit for molecular simulation and modeling (>1.5 million downloads, >2400\ncitations, >1M deployed instances). Its Python API makes it widely popular as both an application (for\nmodelers) and a library (for developers), while its C/C++/Fortran bindings enable major legacy\nsimulation packages to use OpenMM to provide high performance on modern hardware. OpenMM has\nbeen used for probing biological questions that leverage the $20B global investment in structural data\nfrom the PDB at multiple scales, from detailed studies of single disease proteins to superfamily-wide\nmodeling studies and large-scale drug development efforts in industry and academia. In addition to\nhaving a very large user base, OpenMM is an essential component of many high-impact projects, such\nas AlphaFold2 and Folding@home.\nThe first period of this grant enabled OpenMM to transition toward a community governance and\nsustainable development model, build a highly popular quantum chemical dataset that has enabled the\ncommunity to build accurate machine learning (ML) potentials that deliver QM-level accuracy, and\nintegrate support for fast GPU-accelerated protein:ligand simulations that make use of these ML\npotentials but can still achieve fast near-molecular mechanics (MM) speeds. In the next period, we\npropose to build on these successes to generate much more extensive datasets, integrate multiple\nother ML potentials to greatly expand the application domain they can be used for, and further\naccelerate and parallelize these simulations. We also aim to integrate key methodological\nimprovements to improve accuracy for drug discovery applications. To be maximally responsive to the\ncontinually growing needs of the large OpenMM user community, we also aim to onboard a new\ndeveloper focused on implementing community-requested features. To ensure OpenMM remains\nhighly relevant to the modern machine learning revolution, we will continue to expand the ability of\nOpenMM to interoperate with modern ML frameworks such as TensorFlow, PyTorch, and JAX.",
      "project_tags": "SCHOOLS OF ARTS AND SCIENCES",
      "start_date": "2025-11-13",
      "end_date": null,
      "external_id": "2R01GM140090-05"
    },
    {
      "project_title": "Uncovering Heterogeneity in Individual Treatment Responses via Causal Machine Learning",
      "project_description": "PROJECT SUMMARY/ABSTRACT\nClinical recommendations for the management of diseases are mostly based on the average treatment effects\nobserved in randomized controlled trials. However, the beneficial effects of most treatments vary across\nindividuals. Identifying the factors contributing to treatment response heterogeneity is crucial for improving\nmechanistic understanding of treatment-disease interactions and optimizing patient outcomes. Recent\nadvances in high-throughput technologies in biology and the development of large-scale databases provide an\nunprecedented opportunity for a more comprehensive understanding of mechanisms underlying inter-individual\nvariations in treatment responses. Several methods, including subgroup analyses and summary score-based\nanalyses, have been used to assess treatment response heterogeneity. To handle the high dimensionality of\ncovariates, machine learning methods have also been developed to assess treatment heterogeneity. However,\ndespite tremendous advancements in machine learning, two key limitations have hindered a large-scale\ndeployment of the current methods to discover markers underpinning treatment heterogeneity from big data.\nFirst, the current approaches can fail to uncover strong but unexpected predictors of treatment response\nheterogeneity. A key problem is that counterfactual treatment responses for an individual under two possible\nstrategies cannot be directly identified. To make progress, a common approach is to compare the average\nobserved treatment responses across subgroups of individuals, defined either based on one or multiple clinical\nvariables. Nonetheless, such approaches can fail to uncover true signatures for treatment heterogeneity.\nSecond, the current methods for predicting treatment heterogeneity often result in models with limited\ngeneralizability. A key reason is that participants in the source population data (on which models are\ndeveloped) are not a random sample from the target population (on which models will be deployed). When the\nsource population data are not representative of the target population and treatment responses vary across\nfactors that influence participation, algorithms that can tailor the model for use in the new target population will\nrequire cutting-edge tools in data science. To address these challenges, we propose novel causal machine\nlearning methods that will enable the identification of markers (and their complex relationships) for individual\ntreatment responses, with algorithms adaptable to a new target population. This project will combine\ntheoretical developments with large-scale simulation studies and empirical evaluations on treatment for\npatients with stable coronary artery diseases. Successful completion of the proposed research will equip\ninvestigators with powerful methods to unlock the full potential of big data, advance our understanding of\nmechanisms for treatment response heterogeneity, and ultimately improve strategies for preventing and\nmanaging a wide range of health conditions and diseases.",
      "project_tags": "SCHOOLS OF MEDICINE",
      "start_date": "2025-11-13",
      "end_date": null,
      "external_id": "5R35GM154888-02"
    },
    {
      "project_title": "Data Mining and Machine Learning Guided QM/MM and QM-Cluster Modeling of Enzymatic Reactions",
      "project_description": "Project Summary/Abstract\nComputational modeling methods have been widely applied in protein structure prediction, drug\ndiscovery and enzyme bioengineering to provide atomic-level insight into enzymatic reactions and\nfunctions. Accuracy and efficiency are the two goals that motivate the development of new\nmethods in this field. However, the methodological best practices are still lacking in achieving high\nthroughput and accuracy. In quantum mechanics/molecular mechanics (QM/MM) and QM-cluster\nenzyme modeling, series of decisions such as molecule partitioning into QM and MM regions,\nprotonation states of residues, and computational setting rely on good understanding of the\nproblem and knowledge of the enzyme as well as available computational methods. In this\nproposed project, machine learning methods will be applied in computational enzyme modeling\nfor a better and more systematic solution. The proposed project is innovative as it combines a)\ndata mining and machine learning on published experimental and computational works which will\nefficiently and systematically collect knowledge for research; b) machine learning methods can\nweigh different components of computational modeling and make optimal decisions automatically;\nc) the results of this work will provide a rational strategy for accurate and efficient QM/MM and\nQM-cluster simulations in future studies of different protein systems, drug design and even other\nscientific research domains. The proposed project will focus on two enzyme systems that will\nserve as case studies: a) Chorismate Mutase which is a potential target for designing antibiotics\nand b) the Cytochrome P450 superfamily of metalloenzymes which are largely involved in drug\nmetabolism via various reaction mechanisms.",
      "project_tags": "SCHOOLS OF ARTS AND SCIENCES",
      "start_date": "2025-11-13",
      "end_date": null,
      "external_id": "5R35GM145206-04"
    },
    {
      "project_title": "Multi-modal unsupervised embeddings to advance machine learning in healthcare",
      "project_description": "PROJECT SUMMARY\nIntegrating high-dimensional and heterogenous biomedical data, such as electronic health\nrecords (EHRs), molecular data, imaging, and free text, is a key challenge for making robust\ndiscoveries that transform healthcare. Current work in the literature commonly analyze\nbiomedical data types separately, focus on small disease-related cohorts of patients, and rely on\ndomain experts and manual clinical feature selection in an ad hoc manner. Although\nappropriate in some situations, supervised definitions of the feature space scale poorly, do not\ngeneralize well, include inherent biases, and miss opportunities to discover novel patterns and\nfeatures. To address these issues, we will develop novel methods based on unsupervised\nmachine learning to derive low-dimensional vector-based representations, i.e., “embeddings”, of\nmedical concepts and patient clinical histories from large- scale, multi-modal and domain-free\nbiomedical datasets. These pre-computed representations aim to overcome common biases due to\npopulation, supervised labeling, and specific hospital operation processes. These multi-modal\nembeddings can be fine-tuned and applied to a number of specific predictive tasks,\nimproving scalability, generalizability and effectiveness of machine learning models in\nhealthcare. In particular, we will first develop methods based on unsupervised learning to create\nmulti-modal embeddings of medical concepts using heterogeneous EHRs, linked biobanks and\nelectrocardiogram waveform data, from the diverse population of five hospitals within the Mount\nSinai Health System in New York, NY, and publicly available medical knowledge. We will then\ncreate a scalable framework to compute unsupervised multi-modal embeddings that can\nsummarize patient clinical histories and lead to subtyping and patient stratification. We will also\ndevelop a federated learning system to share, visualize, and combine embeddings generated\nseparately at different medical institutes to capture a larger and more diverse population and\nclinical landscape. We will apply embeddings to advance methods for EHR-based disease\nphenotyping, onset prediction, and subtyping. While tested on EHRs, genetic and waveform data\nfrom linked repositories, and medical knowledge, the proposed approaches will be easily\nextendable to include other data, such as clinical images. This project will represent a step\ntowards the next generation of ML in healthcare ML that can (i) scale to billions of patients, (ii)\nembed complex relationships of multi-modal data, and (iii) create less biased disease\nrepresentations by securely learning from patients across institutions via federated learning.",
      "project_tags": "SCHOOLS OF MEDICINE",
      "start_date": "2025-11-13",
      "end_date": null,
      "external_id": "5R01LM013766-04"
    },
    {
      "project_title": "Machine Learning Models for Identifying Neural Predictors of TMS Treatment Response in MDD",
      "project_description": "Transcranial magnetic stimulation (TMS) is an effective and easy-to-tolerate treatment for major depressive\ndisorder (MDD). TMS is costly and time-intensive so identifying markers of response would reduce financial and\npsychological burden. Further, treatment response is highly variable. Clinical and diagnostic heterogeneity of\ndepression contributes to significant variability in neural markers of response. The literature on neural markers\nis complicated by variability in TMS intensity and targets, which may further modify response. Electrical field\nmodels estimate the degree to which a target is stimulated by considering both the intensity and structural\ninformation of each participant but at this time there are no studies that have investigated the association\nbetween brain electrical fields and treatment response. Moreover, the neurobiological correlates of\ndorsolateral (dlPFC) TMS treatment response are not well understood. Machine learning may be able to help us\nunderstand these complex set of features and their association to treatment response. Thus to appropriately\npersonalize treatments, I will develop a data-driven machine learning model that uses the following: (1) pre-\ntreatment resting state connectivity that reflects circuit dysregulation; (2) electrical field modeling to estimate\nthe electrical field or voltage on individual patient’s brain, as a marker of sufficiency of stimulation; and (3)\nexpected target network connectivity as a marker of target engagement. We have previously demonstrated\nfeasibility of machine learning to predict antidepressant response in MDD. We will optimize and expand a model\ndeveloped on archival University of Toronto data that predicted dlPFC TMS response. We will validate this\nexternally on three sets of data: data we collect at University of Pittsburgh, archival data from Brown University,\nand sham TMS data. As an exploratory aim, we will identify whether our model that predicts dlPFC TMS\ntreatment response is capable of predicting response to dmPFC TMS stimulation. During my PhD in\nBioengineering, I developed kernel-based machine learning models to personalize neural networks markers of\nantidepressant response. Given the clinical and neural heterogeneity of depression, I will leverage my machine\nlearning and neuroimaging experience by receiving training in advanced optimization approaches and\ndepression neurobiology to identify stable, reproducible neural predictors of TMS treatment response to achieve\nclinically translatable personalized treatments. This will allow me to develop optimized models of treatment\nresponse and facilitate my long-term career goal to develop personalized treatment algorithms using large-scale\ndata. My previous experiences in machine learning, bioengineering, neuroimaging, as well as the\npreliminary understanding of depression uniquely position me to maximize the benefits of training aims\noutlined in this proposal.\n1",
      "project_tags": "SCHOOLS OF MEDICINE",
      "start_date": "2025-11-13",
      "end_date": null,
      "external_id": "5K01MH122741-05"
    },
    {
      "project_title": "Machine-Learning Prediction and Reducing Overdoses with EHR Nudges (mPROVEN)",
      "project_description": "The US continues to grapple with an opioid epidemic, with ~69,700 opioid overdose deaths in 2020. Health\nsystems have instituted multiple interventions to reduce patient risk, many focusing on decreasing unsafe\nopioid prescribing among those viewed as high-risk. However, there are limited tools to identify who is truly at\nhigh risk of overdose, leading to burdensome interventions targeting an overly broad population or missing key\nhigh-risk individuals. Even if those who are at risk can be identified, the interventions lack effective strategies to\nchange clinician behavior, focusing instead on blunt tools to reduce prescribing rather than reduce risk.\nIn prior work, we developed and externally validated machine-learning algorithms that identify patients at high\nrisk of opioid overdose, even if not actively prescribed opioids. Separately, we demonstrated how behavioral\nnudge alerts embedded in the electronic health record (EHR) can be combined with risk prediction tools to\nchange clinician behavior. In this project, we propose to reduce opioid overdose risk by bringing together\nmachine-learning based overdose risk prediction and behavioral nudges through a scalable EHR intervention\nto improve clinician prescribing behavior. In a large academic health system (UPMC), we propose the following\nspecific aims: (1) Incorporate our previously validated machine learning algorithm into the EHR to predict 3-\nmonth risk of opioid overdose; (2) Pilot test a clinician-targeted behavioral nudge intervention in the EHR for\npatients at high predicted risk for opioid overdose; (3) Evaluate the effectiveness of providing risk scores in the\nEHR with and without a behavioral nudge to improve opioid prescribing safety and reduce overdose risk.\nIn Aim 1, we will apply our gradient boosting machine overdose prediction algorithm to the UPMC Epic-based\nEHR. We will optimize the algorithm for use in UPMC primary care practices, addressing model accuracy and\nalgorithmic biases. In Aim 2, we will combine the risk score generated by our algorithm with clinician nudges in\nthe EHR, using a 3-phase pilot with focus groups, silent testing, and live testing in 3 primary care practices.\nThe nudge intervention will target clinicians caring for high-risk patients and will use active choice prompts for\nnaloxone and accountable justifications for opioid and benzodiazepine prescribing. In Aim 3, we will conduct a\ncluster randomized trial in 45 UPMC primary care practices, with 3 arms: (1) usual care; (2) EHR-embedded\nrisk score; 3) EHR-embedded risk score coupled with the nudge from Aim 2. The EHR-embedded risk score\narm will consist of an alert in the EHR that identifies the patient as high risk for overdose. In the risk score\ncoupled with nudge arm, a similar EHR alert about high-risk status will flag, along with the nudges from Aim 2.\nThe primary outcome will be a composite of 3 prescribing practices associated with reduced risk of overdose:\nnaloxone prescription, opioid dosage <50MME per day, and no opioid/benzodiazepine overlap.\nOur proposal builds on our prior NIDA-funded work and experience with nudge interventions and is aligned\nwith NIDA’s strategic goals to develop and test novel strategies for preventing opioid misuse and overdose.",
      "project_tags": "SCHOOLS OF MEDICINE",
      "start_date": "2025-11-13",
      "end_date": null,
      "external_id": "5R01DA044985-07"
    },
    {
      "project_title": "Unraveling heterogeneity of molecular mechanisms in cellular motility and morphodynamics by machine learning",
      "project_description": "PROJECT SUMMARY/ABSTRACT\nLive cell imaging has revolutionized the study of dynamic cellular processes, enabling researchers to gain\nvaluable functional insights that would be impossible to obtain from static images. The recent advances in\nmicroscopy technology have made it possible to acquire an unprecedented amount of live cell image data at\nhigh spatiotemporal resolutions. However, this abundance of data has brought new challenges, particularly\nconcerning phenotypic and causal heterogeneity. This heterogeneity can complicate the analysis and\ninterpretation of the data, making it challenging to identify critical mechanistic details and understand how\ncellular processes function in different conditions. To address this issue, we have been developing machine\nlearning platforms that can deconvolve the heterogeneity of live cell images at subcellular and cellular levels.\nHowever, there are still many challenges in analyzing live cell heterogeneity in greater detail. First,\nconventional feature selection/learning that aids in classifying known phenotypes could eliminate biologically\nmeaningful heterogeneity. Second, current cell biology research focuses primarily on mechanisms that\nproduce similar average effects across various populations, which could suffer from causal heterogeneity.\nEven with the significant progress made in single-cell biology, the discovery of causal mechanisms at the\nsingle-cell resolution is still not fully achieved. Finally, the substantial heterogeneity in cell motility and\nmorphodynamics poses a challenge to obtaining integrated and systematic understandings of these\nprocesses, despite their clear significance in fields such as tissue regeneration and cancer metastasis. To\novercome these challenges, we propose to advance current machine learning methods to i) identify features\nthat preserve subtype heterogeneity while being discriminative between known phenotypes, ii) acquire causal\ndatasets of live cell images by tracking cells before and after optogenetic treatment, and iii) deconvolve the\ncausal heterogeneity of single live cells by integrating time-series modeling and deep learning. We will apply\nthese methods to map out single-cell mechanisms governing cellular motility and morphodynamics of various\ncell types, which will be valuable resources for the cell biology community. Then, we will characterize how\nmechanical and metabolic perturbations can shape the heterogeneous landscapes of cell motility and\nmorphodynamics, providing new insights into the underlying mechanisms integrating these processes.",
      "project_tags": "Independent Hospitals",
      "start_date": "2025-11-13",
      "end_date": null,
      "external_id": "5R35GM133725-08"
    },
    {
      "project_title": "AI-Campus Workshops: Revolutionizing Healthcare with AI and Machine Learning",
      "project_description": "The healthcare sector is undergoing a transformation driven by artificial intelligence and\nmachine learning (AI/ML) technologies, which offer potential for enhancing research,\noptimizing patient outcomes, and increasing healthcare systems' efficiency. However,\nmany researchers face limited access to resources and opportunities in this field. We\npropose a multi-faceted approach, including online competitions and annual workshops\ncatering to a wide range of participants. We have a strong track record of engaging with\nbroad participation through AI-Campus and national competition organization\nexperiences. We have organized events such as the iDASH genomic privacy workshop\nand encouraged students to participate in the Dream challenge. Our proposed series of\nevents, \"AI-Campus Workshops: Revolutionizing Healthcare with AI and Machine\nLearning,\" will build upon this track record of success. Aim 1 focuses on creating annual\ncompetitions for healthcare outcome improvements, designing datasets that represent\nreal-world problems, and providing opportunities to broad participants. Aim 2 involves\norganizing annual workshops on the latest AI/ML advances in healthcare, inviting\nspeakers, and offering experience with the latest tools and technologies. Aim 3 centers on\nengaging broad participates, to ensure broad representation in our AI/ML healthcare\ninitiatives. Through these aims, we will empower participants with essential skills,\nknowledge, and connections needed to excel in the healthcare AI/ML landscape. Our\nvision is to foster a community of researchers and practitioners committed to advancing\nAI/ML in healthcare. By facilitating broad participation, education, and collaboration, we\naim to make a significant impact on AI/ML for healthcare and nurture a community that\npropels progress and innovation in healthcare to benefit everyone.",
      "project_tags": "Independent Hospitals",
      "start_date": "2025-11-13",
      "end_date": null,
      "external_id": "5R13LM014478-02"
    },
    {
      "project_title": "SCH: Novel Multi-View Statistical Machine Learning for Alzheimer's Disease",
      "project_description": "Alzheimer’s disease (AD) is the most common type of dementia without curative medications. Early\ndetection of AD is thus essential for timely intervention and effective treatment development. Multi-view\ndata provides a transformative approach to enhance the understanding, diagnosis, and prediction of AD.\nThis research aims to develop three novel statistical machine learning methods for AD research using\nmulti-view imaging, genomic, and clinical data, focusing on multi-view brain and genomic network analysis,\nsignificant differential feature testing, and diagnosis and survival analysis. The specific aims of this\nproposal include: 1. Develop a novel high-dimensional multi-view data decomposition based on\nuncorrelated common and distinctive latent factors (C&DLFs) to construct multi-view networks, with\napplication to comparing brain and genomic networks across AD statuses; 2. Develop an optimal false\ndiscovery rate (FDR) control method based on a novel semi-parametric hidden Markov random field for\nhigh-dimensional spatial multiple testing, with application to identifying significant brain and genomic\ndifferences across AD statuses; 3. Develop a highly accurate deep-learning-based diagnosis and survival\nframework for high-dimensional tabular data, incorporating feature selection and view ablation to enhance\ncost-effectiveness and data accessibility in clinical practice; 4. Apply the three proposed methods to four\nlarge-scale AD-related datasets and disseminate the methods with an open, efficient software package.\nThe three novel methods in our project will undergo rigorous theoretical and numerical analyses. The\nresearch team’s extensive expertise in multi-view data analysis, network analysis, imaging genetics, high-\ndimensional statistics, deep learning, and AD research will make significant contributions to the project’s\nsuccess.\nRELEVANCE (See instructions):\nThe research goal is to develop three novel statistical machine learning methods for Alzheimer’s disease\n(AD) using multi-view imaging, genomic, and clinical data. These methods will focus on multi-view brain\nand genomic network analysis, significant differential feature testing, and diagnosis and survival analysis.\nThe proposed project will enhance our understanding of neuro-genetic associations in AD and significantly\ncontribute to biomarker discovery, early detection, and improved patient survival in AD.",
      "project_tags": "SCHOOLS OF PUBLIC HEALTH",
      "start_date": "2025-11-13",
      "end_date": null,
      "external_id": "1RF1AG098697-01"
    },
    {
      "project_title": "Predicting ECMO NeuroLogICal Injuries using mAchiNe Learning (PELICAN)",
      "project_description": "Project Summary\nExtracorporeal Membrane Oxygenation (ECMO) is a form of cardiopulmonary bypass used in\ncritically ill children and adults to support the heart and lungs when conventional therapies fail.\nMore than 79,762 children worldwide have been supported to date, and global use of this tool is\nexpanding. Advances in ECMO and critical care have improved survival of otherwise fatal\nillnesses, thereby unmasking neurologic injury which itself reduces survival by 50-60% and leads\nto significant long-term neurologic morbidity. The mechanisms of ECMO-related cerebral injuries\nare poorly understood. Existing research focuses on evaluating discrete elements, such as\nunderlying illness, coagulation abnormalities, anticoagulation management, or markers of end-\norgan perfusion as factors associated with brain injury. Prior studies have not considered the\ntemporal and dynamic element of clinical events that may play a large role in the genesis of brain\ninjury, and few have explored which variables could predict significant neurologic injury without\nthe bias of pre-selecting variables of interest. Machine learning is a form of artificial intelligence\nthat employs algorithms to discover patterns in an iterative manner directly from input data: in the\ncontext of ECMO, it can identify dynamic patterns and relationships between variables prior to\nneurologic injury.\n The long-term goal of this research is to identify modifiable bedside predictors of neurologic\nimpairment and thereby drive the development of early interventions to improve neurologic\noutcomes of children undergoing ECMO. Towards this goal, we have assembled a multi-\ndisciplinary team with clinical and computational expertise. Our central hypothesis is that a robust\nrisk predictive model for SNI in ECMO patients can be developed based on the physiological and\nlaboratory data routinely collected in real-world clinical settings and that this model can be used\nto identify parameters of SNI for potential intervention. This proposal will utilize advanced machine\nlearning algorithms to build this prediction model in a large multicenter cohort (0-18 years, n=750).\nIn Aim 1, we will use novel probabilistic machine learning algorithms to train and develop a model\nto predict SNI by neuroimaging. In Aim 2, we will validate and refine the model from Aim 1 using\nneuroimaging scores and explore a personalized anytime query algorithm that predicts the timing\nand type of SNI. This collaborative proposal between clinical and computational scientists will lay\nthe groundwork for a neuroprotective interventional study by identifying modifiable risk factors to\nimprove the tragically high neurologic morbidity and mortality in ECMO survivors.",
      "project_tags": "SCHOOLS OF MEDICINE",
      "start_date": "2025-11-13",
      "end_date": null,
      "external_id": "5R01NS133142-03"
    },
    {
      "project_title": "Machine learning approaches for the detection of emergency department patients with opioid misuse",
      "project_description": "Project Summary/Abstract\nPatients with opioid misuse disproportionately utilize emergency health services and are at increased risk for\npremature death. The timely and accurate identification of patients with opioid misuse in the Emergency\nDepartment (ED) is critical to provide evidence-based interventions to decrease mortality. Challenges to opioid\nmisuse detection in the ED include provider time constraints, inconsistent screening approaches, and patient\nbarriers to self-reporting. Advanced analytic techniques such as machine learning and cluster analyses offer\npromise in efficiently characterizing and identifying patients with opioid misuse during their ED encounter by\nleveraging data within the electronic health record (EHR) and the prescription drug monitoring program (PDMP).\nThe role of machine learning approaches utilizing multiple data sources to identify ED patients with opioid misuse\nhas yet to be fully explored. In aim 1, multiple machine learning algorithms using ED encounter data will be\ndeveloped for the identification of opioid misuse. Models will be systematically assessed for social biases and\nmitigation strategies implemented to ensure equity in model performance. In aim 2, the inclusion of longitudinal\nPDMP data for the identification of ED patients with opioid misuse will be evaluated by building models from both\ndata sources utilizing ensemble stacking methods. Finally, in aim 3, an unsupervised latent class analysis model\nwill be built to identify clinically relevant subphenotypes of ED patients with opioid misuse, describe their\ncharacteristics, and determine patient-oriented outcomes. An innovative approach to the detection of ED patients\nwith opioid misuse will be pursued by rigorously testing machine learning models utilizing multiple data sources,\nconducting social bias assessments prior to clinical deployment, and characterizing latent groups of patients with\nopioid misuse. The candidate for this Mentored Patient-Oriented Career Development Award (Dr. Neeraj\nChhabra) possesses a strong foundation in emergency care, medical toxicology, substance use research, and\nbiostatistics. Through this K23, he will further develop skills in data science to build comprehensive and scalable\nmodels spanning multiple data domains for the identification of patients with opioid misuse. The multidisciplinary\nmentorship team led by his primary mentor (Dr. Niranjan Karnik) and co-mentors (Dr. Majid Afshar, Dr. Harold\nPollack, and Dr. Gail D’Onofrio) consists of nationally renowned experts in the fields of substance use research,\nmachine learning, natural language processing, and clinical ethics. Through an integrated program of formal\ncoursework, ethics training, mentorship, and research, Dr. Chhabra will develop the skillset necessary to\ncomplete these aims and transition to independent investigation. His proposal takes full advantage of the\ncombined resources provided by the affiliated institutions of Cook County Health and Rush University Medical\nCenter. Dr. Chhabra’s long-term goal is to utilize machine learning techniques to focus treatments and resources\ntowards patients with opioid misuse within the ED setting. This K23 award provides the necessary foundation to\npursue this goal and will form the basis for future R01 proposals evaluating the clinical impact of these models.",
      "project_tags": "SCHOOLS OF MEDICINE",
      "start_date": "2025-11-13",
      "end_date": null,
      "external_id": "5K23DA055061-04"
    },
    {
      "project_title": "Predicting Viral Spillover Risk using Machine Learning and Adversarial Mutation",
      "project_description": "Project Summary\nThe potential for animal viruses to spill over into humans represents a persistent, consequential threat to\nhuman global health. However, our ability to predict which viruses are most likely to “jump” into humans is\ncurrently limited. Computational approaches are a potential solution to this problem, and early results are\npromising. Nevertheless, most computational approaches are “static” with respect to virus evolution - they\nendeavor to predict zoonotic potential of viruses at a single point in time (the point at which viruses were\nidentified or sequenced), but they do not account for evolution, which is a hallmark of virus biology.\nThis project will fill this methodological gap by offering a new approach inspired by adversarial machine\nlearning. Adversarial machine learning is a broad area of research that includes methods designed to identify\nsmall changes to a learned model’s input that significantly change its output. We will develop and apply\nadversarial machine learning to the following prediction task: given genomic protein sequences from a non-\nhuman animal virus, use a learned model to predict if the virus is likely to be infectious to humans, or how\nextensively it would have to mutate to become infectious Our proposed approach will notably advance the\nstate of the art by (i) considering not just the human-infection risk for a “static” viral sequence but also the\nspillover risk attributable to evolutionary variants, (ii) applying and developing methods to characterize and\nexplain the risk prediction for a given virus, and (iii) developing and evaluating predictive models based on\nstate-of-the-art neural networks for protein sequences.",
      "project_tags": "SCHOOLS OF MEDICINE",
      "start_date": "2025-11-13",
      "end_date": null,
      "external_id": "1R21AI182816-01A1"
    },
    {
      "project_title": "Machine Learning Risk Prediction of Kidney Disease After Extremely Preterm Birth",
      "project_description": "PROJECT SUMMARY\nThe overall goals of this 3 year mentored patient-oriented research career development award are to develop\ntools to improve recognition of kidney disease risks among extremely preterm born children and to support the\ndevelopment of Dr. Keia Sanderson into an independent investigator. Dr. Sanderson is a motivated clinical\nresearcher at the University of North Carolina at Chapel Hill (UNC), with a specific interest in early recognition\nof kidney disease in children. Over the next 3 years, Dr. Sanderson will work with her mentorship committee\ntoward her goal of independence building upon her prior 3 years of KL2-supported training. Her mentorship\ncommittee includes experts in long-term neonatal outcomes research (O’Shea, Laughon), neonatal nephrology\n(Askenazi), machine learning (Kosorok), qualitative research (Flythe), and clinical decision support science\n(Kistler). Each member has an established track record of mentoring junior faculty, consistent peer-reviewed\nsupport, and high research productivity. Dr. Sanderson’s career development objectives are to: 1) gain multi-\ncenter research leadership experience; 2) develop skills in machine learning methods for large data risk\nstratification; 3) develop qualitative research skills to support practical application of machine learning models;\n4) acquire skills in research mentorship; and 5) improve publication and grant writing in preparation for NIH\nR01 applications. The research and training environment at UNC is well established to support these\nobjectives. To achieve her career development objectives, Dr. Sanderson will participate in structured\ncoursework, conduct mentored research, and workshops through North Carolina Translational and Clinical\nSciences Institute R-Writing Group. The specific aims of this research project are to 1) utilize machine learning\napproaches within large databases of prenatal, neonatal, and early life exposure variables to predict kidney\ndisease in adolescents born extremely premature; 2) develop and evaluate the usability and acceptability of a\nprototype web-based risk stratification tool for pediatric kidney disease after extremely preterm birth using\nvariables hypothesized to predict kidney disease. Expanding on two existing prospective cohorts (Extremely\nLow Gestational Age Newborn-Environmental influences on Child Health Outcomes (ELGAN-ECHO) and the\nPreterm Erythropoietin Neuroprotection Trial (PENUT) cohorts), Dr. Sanderson will utilize clinical variables to\nidentify the combination of “at-highest risk,” and “at-risk” predictors for pediatric chronic kidney disease in\nchildren after extremely preterm birth. This research will be the basis for R-level NIH applications to develop a\nfinalized web-based risk prediction tool informed by this proposal for public dissemination, to expand the use of\nmachine learning derived risk stratification tools to other medically complex pediatric populations, and to test\nwhether use of risk prediction tools increases the use of critical interventions (e.g. angiotensin converting\nenzyme inhibitors) to prevent kidney disease progression in high risk children.",
      "project_tags": "SCHOOLS OF MEDICINE",
      "start_date": "2025-11-13",
      "end_date": null,
      "external_id": "5K23DK131289-03"
    },
    {
      "project_title": "Analytics & Machine-learning for Maternal-health Interventions (AMMI): A Cross-CTSA Collaboration",
      "project_description": "PROJECT SUMMARY\nAfrican-American women across the US experience alarmingly higher rates of maternal mortality than\ntheir white counterparts. Factors associated with social determinants of health (SDoH), including\neducation, housing, transportation, and nutrition are recognized as potentially contributiing to this\ndisparity in maternal health outcomes, along with clinical risk factors including hypertension and heart\ndisease. However, the complex associations among these factors, along with the causal role they play in\nincreased risk for maternal mortality, are not well understood, nor are there comprehensive health care\ninterventions that take these combined factors into account to provide decision and communication\nsupport for patients, providers, and community support workers. The Analytics and Machine-learning\nfor Maternal-health Interventions (AMMI) initiative, a collaborative effort from researchers at UNC-\nChapel Hill, Duke, and Wake Forest, aims to address these gaps by developing a machine learning-\nenhanced health technology framework to reduce downstream risk of maternal mortality in African-\nAmerican women. By integrating data across the three institutions that includes both clinical and SDoH\nfactors, and by building machine learning applications grounded in this data, AMMI’s goals are to: 1)\nclarify and track contributions of biological, clinical, and SDoH factors toward specific maternal\nmorbidities associated with eventual mortality, 2) conduct efficient and accurate risk predictions to\ndetermine whether patients fall into defined target risk groups, and 3) translate these risk predictions\ninto interventions appropriate for providers, patients, and community support organizations. A key\nfocus of the initiative is to create an advanced technology infrastructure supporting connectivity and\ncommunication among these three types of stakeholders, with the goal of building trust and awareness\nbased on automatically curated decision support aids and ultimately mitigating patient risk. To this end,\nAim 1, focused on establishing system requirements, begins with the formation of a stakeholder group\nthat brings together patient, provider, and community support organization representatives to engage\nin design and evaluation with AMMI researchers throughout the project. Aim 2 focuses on systems\ndevelopment, including the creation of 1) a custom-built clinical and SDoH data mart, 2) clinical decision\nsupport software using machine learning algorithms, and 3) three user-facing apps aimed at providers,\npatients and community support personnel, and AMMI researchers. Aim 3 focuses on pilot-level\ndeployment of the system, integrating the AMMI apps through Epic to provide informational\ninterventions to providers, patients, and community support personnel. Aim 4 engages stakeholders in\nformative and summative evaluation during and after the deployment phase (Aim 3), including both\ntesting of the software function and measurement of the impact of AMMI interventions on end users.",
      "project_tags": "SCHOOLS OF MEDICINE",
      "start_date": "2025-11-13",
      "end_date": null,
      "external_id": "5U01TR003629-04"
    },
    {
      "project_title": "Machine Learning for Precision Treatments in Schizophrenia",
      "project_description": "Project Summary/Abstract Schizophrenia is associated with psychotic symptoms, mood disturbances,\ndeficits in cognition, comorbidities, significant social and functional impairment and is a leading cause of\ndisability in the U.S. and worldwide. Although antipsychotic medications and psychosocial treatments are\neffective for some symptoms of schizophrenia, effective regimens for all symptoms are not established. The\nprimary limitation of treatment guidelines is reliance on RCTs that test limited treatments and their effects on\nfew symptoms and comorbidities. Trials of treatments administered to address all aspects of impairment is\nprohibitively complex. Data driven machine learning (ML) can address this gap using large observational\ndatasets with information about complex and effective regimens used in real-world practice. ML can cluster\nindividuals with shared characteristics and identify unique regimens administered for their psychiatric and\nclinical comorbidities. These new treatment regimens are possible precision treatments. ML algorithms can\nthen predict critical patient-centered outcomes for these different clusters (or classes) administered these\ntreatment regimens. Examining the comparative effectiveness of these treatment regimens that predict critical\noutcomes is an essential next step. Unique pharmacoepidemiologic methods with observational data can\nsimulate clinical trials. Propensity score methods address confounding, mimicking balance achieved by\nrandomization in RCTs. These tools will determine which precision treatment regimens are the most effective\nfor the classes in these datasets. Relevance of ML findings depends on data quality. Claims have the largest,\nmost nationally representative samples reflecting real-world community practice patterns but use billing codes\nnot originally designed for research. Electronic health records (EHR) are extensive but limited due to bias from\nincomplete records with uncertain accuracy and complexity due to their granular level of detail. This proposal\nwill establish the strengths and limitations of these dataset types by conducting ML analyses on exemplar\ndatasets, a Medicaid Analytic eXtract (MAX) national sample, and the Observational Health Data Sciences and\nInformatics (OHDSI) network New York-Presbyterian Hospital (iNYP) EHR. An enhancement to this project will\ncompare more traditional multivariate and regression techniques to the ML findings identifying whether ML\nprovides additional information. To address the “research-practice” gap the ML results will be translated into\npersonalized treatment rules to inform clinical practice for schizophrenia treatment. After training in\nunsupervised and supervised learning in Training Aims A and B, Research Aim 1 will identify classes and their\nadministered treatments in the datasets and Research Aim 2 will predict outcomes of those treatments: time to\nemergency department visit, time to re-admission and incidence of comorbidities. Research Aim 3 will use\npharmacoepidemiologic methods learned in Training Aim C to compare effectiveness of the treatments,\nsupporting an R01 submitted at the end of this K-award to test effectiveness in an international EHR dataset.",
      "project_tags": "Independent Hospitals",
      "start_date": "2025-11-13",
      "end_date": null,
      "external_id": "5K23MH129628-04"
    }
  ],
  "workedon": [
    {
      "person_email": "nih_1858208@profiles.nih.gov",
      "project_title": "Machine Learning for Ventricular Arrhythmias",
      "project_role": "Principal Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 3R01HL162260-03S1"
    },
    {
      "person_email": "nih_77918177@profiles.nih.gov",
      "project_title": "Designing Personalized Formulations with Machine Learning",
      "project_role": "Principal Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 5R35GM151255-03"
    },
    {
      "person_email": "nih_1858208@profiles.nih.gov",
      "project_title": "Machine Learning for Ventricular Arrhythmias",
      "project_role": "Principal Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 5R01HL162260-03"
    },
    {
      "person_email": "nih_12329894@profiles.nih.gov",
      "project_title": "Interpretable machine learning for understanding the neural control of movement",
      "project_role": "Principal Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 5R00NS119787-05"
    },
    {
      "person_email": "nih_10947803@profiles.nih.gov",
      "project_title": "Machine Learning and Image Analysis Core",
      "project_role": "Principal Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 2P30AG038070-16"
    },
    {
      "person_email": "nih_12435280@profiles.nih.gov",
      "project_title": "Machine Learning and Control Principles for Computational Biology",
      "project_role": "Principal Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 5R35GM143056-05"
    },
    {
      "person_email": "nih_14571299@profiles.nih.gov",
      "project_title": "Multiethnic machine learning brain signatures of ADRD",
      "project_role": "Principal Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 5R01AG080821-04"
    },
    {
      "person_email": "nih_16345702@profiles.nih.gov",
      "project_title": "Explainable Machine Learning to Guide Prefrontal Brain Stimulation",
      "project_role": "Principal Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 5R01MH125429-04"
    },
    {
      "person_email": "nih_14086113@profiles.nih.gov",
      "project_title": "Explainable Machine Learning to Guide Prefrontal Brain Stimulation",
      "project_role": "Co-Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 5R01MH125429-04"
    },
    {
      "person_email": "nih_14074702@profiles.nih.gov",
      "project_title": "Robust, Generalizable, and Fair Machine Learning Models for Biomedicine",
      "project_role": "Principal Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 5R35GM142879-05"
    },
    {
      "person_email": "nih_11587919@profiles.nih.gov",
      "project_title": "Machine learning approaches for the discovery, repurposing, and optimization of natural products with therapeutic potential",
      "project_role": "Principal Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 5R35GM146987-04"
    },
    {
      "person_email": "nih_10363722@profiles.nih.gov",
      "project_title": "Integrative Machine Learning for Common Fund Spatial Omics",
      "project_role": "Principal Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 1R03OD039980-01"
    },
    {
      "person_email": "nih_15924210@profiles.nih.gov",
      "project_title": "Machine Learning Models of Appropriate Medevac Utilization in Rural Alaska",
      "project_role": "Principal Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 5K08MD016445-04"
    },
    {
      "person_email": "nih_6465196@profiles.nih.gov",
      "project_title": "Machine Learning to Modulate Influenza Immunity",
      "project_role": "Principal Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 1U01AI187059-01"
    },
    {
      "person_email": "nih_8585373@profiles.nih.gov",
      "project_title": "Machine Learning to Modulate Influenza Immunity",
      "project_role": "Co-Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 1U01AI187059-01"
    },
    {
      "person_email": "nih_14479879@profiles.nih.gov",
      "project_title": "Machine Learning to Modulate Influenza Immunity",
      "project_role": "Co-Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 1U01AI187059-01"
    },
    {
      "person_email": "nih_12042562@profiles.nih.gov",
      "project_title": "Using Causal Machine Learning Methods to Inform Tobacco Regulatory Science",
      "project_role": "Principal Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 5K01DA058408-03"
    },
    {
      "person_email": "nih_15861391@profiles.nih.gov",
      "project_title": "SCH: Quantifying and mitigating demographic biases of machine learning in real world radiology",
      "project_role": "Principal Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 5R01CA287422-03"
    },
    {
      "person_email": "nih_2650198@profiles.nih.gov",
      "project_title": "The Short Course on the Application of Machine Learning for Automated Quantification of Behavior",
      "project_role": "Principal Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 5R25MH129298-04"
    },
    {
      "person_email": "nih_14123991@profiles.nih.gov",
      "project_title": "The Short Course on the Application of Machine Learning for Automated Quantification of Behavior",
      "project_role": "Co-Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 5R25MH129298-04"
    },
    {
      "person_email": "nih_14342570@profiles.nih.gov",
      "project_title": "Biology-aware machine learning methods for characterizing microbiome genotype and phenotype",
      "project_role": "Principal Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 5R35GM142725-05"
    },
    {
      "person_email": "nih_14982777@profiles.nih.gov",
      "project_title": "Machine Learning Methods to Predict Cancer Progression and Estimate Treatment Effectiveness",
      "project_role": "Principal Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 5F30CA268631-04"
    },
    {
      "person_email": "nih_78378444@profiles.nih.gov",
      "project_title": "Forecasting emotional disorder symptoms: A dynamical systems and time-series machine learning approach",
      "project_role": "Principal Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 5K23MH132896-02"
    },
    {
      "person_email": "nih_14472306@profiles.nih.gov",
      "project_title": "Analyze: Machine Learning for Mobility Data",
      "project_role": "Principal Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 5P41EB027060-05"
    },
    {
      "person_email": "nih_12001814@profiles.nih.gov",
      "project_title": "Machine learning of biomolecular interactions and the human signaling networks they comprise",
      "project_role": "Principal Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 5R35GM150546-03"
    },
    {
      "person_email": "nih_6356426@profiles.nih.gov",
      "project_title": "Knowledge-guided automated machine learning methods for modeling the interaction of HIV with addictive drugs",
      "project_role": "Principal Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 5R01LM014572-02"
    },
    {
      "person_email": "nih_11340341@profiles.nih.gov",
      "project_title": "Machine-Learning Models for big data omics",
      "project_role": "Principal Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 5R35GM153434-02"
    },
    {
      "person_email": "nih_7983805@profiles.nih.gov",
      "project_title": "Machine learning approaches to predict Acetylcholinesterase inhibition and model applications",
      "project_role": "Principal Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 5R44ES033855-03"
    },
    {
      "person_email": "nih_12484647@profiles.nih.gov",
      "project_title": "Development of Dynamic Resting State Functional Connectivity Machine Learning Framework for Dementia",
      "project_role": "Principal Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 5K25AG071840-04"
    },
    {
      "person_email": "nih_12470438@profiles.nih.gov",
      "project_title": "SCH: Machine learning for personalized preventative intervention in perinatal depression",
      "project_role": "Principal Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 5R01MH139097-02"
    },
    {
      "person_email": "nih_78297124@profiles.nih.gov",
      "project_title": "SCH: Machine learning for personalized preventative intervention in perinatal depression",
      "project_role": "Co-Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 5R01MH139097-02"
    },
    {
      "person_email": "nih_1897930@profiles.nih.gov",
      "project_title": "Analytics, BioStatistics, and Machine Learning Module",
      "project_role": "Principal Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 5P30EY008098-37"
    },
    {
      "person_email": "nih_9260502@profiles.nih.gov",
      "project_title": "Reproducibility statistics and machine learning methods for systematic phenotyping and model integration across animals, organs, and technologies",
      "project_role": "Principal Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 1R01OD039830-01"
    },
    {
      "person_email": "nih_78305570@profiles.nih.gov",
      "project_title": "Trustworthy Machine Learning for Clinical Diagnosis and Decision Support",
      "project_role": "Principal Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 5F30MD020264-02"
    },
    {
      "person_email": "nih_15711428@profiles.nih.gov",
      "project_title": "Personalized Postpartum Hemorrhage Prediction Using Machine Learning And Polygenic Risk Scores",
      "project_role": "Principal Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 5K08HL161326-04"
    },
    {
      "person_email": "nih_8702983@profiles.nih.gov",
      "project_title": "Supporting IGVF by modeling genetics, function, and phenotype with machine learning",
      "project_role": "Principal Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 5U01HG012022-05"
    },
    {
      "person_email": "nih_16609793@profiles.nih.gov",
      "project_title": "Machine learning to predict cure in severe pneumonia episodes",
      "project_role": "Principal Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 5K23HL169815-02"
    },
    {
      "person_email": "nih_11554010@profiles.nih.gov",
      "project_title": "Advanced machine learning models to integrate multi-modal biomedical datasets for gene regulation and precision medicine",
      "project_role": "Principal Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 2R35GM133657-07"
    },
    {
      "person_email": "nih_12509787@profiles.nih.gov",
      "project_title": "From protein structures to effective drugs via machine learning and molecular simulation",
      "project_role": "Principal Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 1R35GM158122-01"
    },
    {
      "person_email": "nih_16448077@profiles.nih.gov",
      "project_title": "Metasurface enhanced and machine learning aided spectrochemical liquid biopsy",
      "project_role": "Principal Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 5R21EB034411-03"
    },
    {
      "person_email": "nih_16325837@profiles.nih.gov",
      "project_title": "OpenMM: Scalable biomolecular modeling, simulation, and machine learning",
      "project_role": "Principal Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 2R01GM140090-05"
    },
    {
      "person_email": "nih_15899764@profiles.nih.gov",
      "project_title": "Uncovering Heterogeneity in Individual Treatment Responses via Causal Machine Learning",
      "project_role": "Principal Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 5R35GM154888-02"
    },
    {
      "person_email": "nih_77904714@profiles.nih.gov",
      "project_title": "Data Mining and Machine Learning Guided QM/MM and QM-Cluster Modeling of Enzymatic Reactions",
      "project_role": "Principal Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 5R35GM145206-04"
    },
    {
      "person_email": "nih_78602757@profiles.nih.gov",
      "project_title": "Multi-modal unsupervised embeddings to advance machine learning in healthcare",
      "project_role": "Principal Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 5R01LM013766-04"
    },
    {
      "person_email": "nih_15085352@profiles.nih.gov",
      "project_title": "Machine Learning Models for Identifying Neural Predictors of TMS Treatment Response in MDD",
      "project_role": "Principal Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 5K01MH122741-05"
    },
    {
      "person_email": "nih_10407141@profiles.nih.gov",
      "project_title": "Machine-Learning Prediction and Reducing Overdoses with EHR Nudges (mPROVEN)",
      "project_role": "Principal Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 5R01DA044985-07"
    },
    {
      "person_email": "nih_10578469@profiles.nih.gov",
      "project_title": "Unraveling heterogeneity of molecular mechanisms in cellular motility and morphodynamics by machine learning",
      "project_role": "Principal Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 5R35GM133725-08"
    },
    {
      "person_email": "nih_9624002@profiles.nih.gov",
      "project_title": "AI-Campus Workshops: Revolutionizing Healthcare with AI and Machine Learning",
      "project_role": "Principal Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 5R13LM014478-02"
    },
    {
      "person_email": "nih_10960996@profiles.nih.gov",
      "project_title": "AI-Campus Workshops: Revolutionizing Healthcare with AI and Machine Learning",
      "project_role": "Co-Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 5R13LM014478-02"
    },
    {
      "person_email": "nih_12609329@profiles.nih.gov",
      "project_title": "AI-Campus Workshops: Revolutionizing Healthcare with AI and Machine Learning",
      "project_role": "Co-Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 5R13LM014478-02"
    },
    {
      "person_email": "nih_16250460@profiles.nih.gov",
      "project_title": "SCH: Novel Multi-View Statistical Machine Learning for Alzheimer's Disease",
      "project_role": "Principal Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 1RF1AG098697-01"
    },
    {
      "person_email": "nih_11025029@profiles.nih.gov",
      "project_title": "Predicting ECMO NeuroLogICal Injuries using mAchiNe Learning (PELICAN)",
      "project_role": "Principal Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 5R01NS133142-03"
    },
    {
      "person_email": "nih_15556443@profiles.nih.gov",
      "project_title": "Machine learning approaches for the detection of emergency department patients with opioid misuse",
      "project_role": "Principal Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 5K23DA055061-04"
    },
    {
      "person_email": "nih_6407230@profiles.nih.gov",
      "project_title": "Predicting Viral Spillover Risk using Machine Learning and Adversarial Mutation",
      "project_role": "Principal Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 1R21AI182816-01A1"
    },
    {
      "person_email": "nih_14907116@profiles.nih.gov",
      "project_title": "Machine Learning Risk Prediction of Kidney Disease After Extremely Preterm Birth",
      "project_role": "Principal Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 5K23DK131289-03"
    },
    {
      "person_email": "nih_8637742@profiles.nih.gov",
      "project_title": "Analytics & Machine-learning for Maternal-health Interventions (AMMI): A Cross-CTSA Collaboration",
      "project_role": "Principal Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 5U01TR003629-04"
    },
    {
      "person_email": "nih_7935014@profiles.nih.gov",
      "project_title": "Analytics & Machine-learning for Maternal-health Interventions (AMMI): A Cross-CTSA Collaboration",
      "project_role": "Co-Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 5U01TR003629-04"
    },
    {
      "person_email": "nih_9714083@profiles.nih.gov",
      "project_title": "Analytics & Machine-learning for Maternal-health Interventions (AMMI): A Cross-CTSA Collaboration",
      "project_role": "Co-Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 5U01TR003629-04"
    },
    {
      "person_email": "nih_12578186@profiles.nih.gov",
      "project_title": "Machine Learning for Precision Treatments in Schizophrenia",
      "project_role": "Principal Investigator",
      "start_date": "2025-11-13",
      "end_date": null,
      "notes": "NIH project 5K23MH129628-04"
    }
  ],
  "belongsto": [
    {
      "department_name": "INTERNAL MEDICINE/MEDICINE",
      "institution_name": "STANFORD UNIVERSITY",
      "effective_start": "2025-11-13",
      "effective_end": null,
      "justification": "NIH project 3R01HL162260-03S1"
    },
    {
      "department_name": "BIOMEDICAL ENGINEERING",
      "institution_name": "DUKE UNIVERSITY",
      "effective_start": "2025-11-13",
      "effective_end": null,
      "justification": "NIH project 5R35GM151255-03"
    },
    {
      "department_name": "NEUROLOGY",
      "institution_name": "NORTHWESTERN UNIVERSITY AT CHICAGO",
      "effective_start": "2025-11-13",
      "effective_end": null,
      "justification": "NIH project 5R00NS119787-05"
    },
    {
      "department_name": "Unknown Department",
      "institution_name": "JACKSON LABORATORY",
      "effective_start": "2025-11-13",
      "effective_end": null,
      "justification": "NIH project 2P30AG038070-16"
    },
    {
      "department_name": "Unknown Department",
      "institution_name": "BRIGHAM AND WOMEN'S HOSPITAL",
      "effective_start": "2025-11-13",
      "effective_end": null,
      "justification": "NIH project 5R35GM143056-05"
    },
    {
      "department_name": "RADIATION-DIAGNOSTIC/ONCOLOGY",
      "institution_name": "UNIVERSITY OF TEXAS HLTH SCIENCE CENTER",
      "effective_start": "2025-11-13",
      "effective_end": null,
      "justification": "NIH project 5R01AG080821-04"
    },
    {
      "department_name": "BIOSTATISTICS & OTHER MATH SCI",
      "institution_name": "UNIVERSITY OF WASHINGTON",
      "effective_start": "2025-11-13",
      "effective_end": null,
      "justification": "NIH project 5R01MH125429-04"
    },
    {
      "department_name": "MISCELLANEOUS",
      "institution_name": "HARVARD MEDICAL SCHOOL",
      "effective_start": "2025-11-13",
      "effective_end": null,
      "justification": "NIH project 5R35GM142879-05"
    },
    {
      "department_name": "CHEMISTRY",
      "institution_name": "VANDERBILT UNIVERSITY",
      "effective_start": "2025-11-13",
      "effective_end": null,
      "justification": "NIH project 5R35GM146987-04"
    },
    {
      "department_name": "BIOSTATISTICS & OTHER MATH SCI",
      "institution_name": "CARNEGIE-MELLON UNIVERSITY",
      "effective_start": "2025-11-13",
      "effective_end": null,
      "justification": "NIH project 1R03OD039980-01"
    },
    {
      "department_name": "EMERGENCY MEDICINE",
      "institution_name": "STANFORD UNIVERSITY",
      "effective_start": "2025-11-13",
      "effective_end": null,
      "justification": "NIH project 5K08MD016445-04"
    },
    {
      "department_name": "BIOSTATISTICS & OTHER MATH SCI",
      "institution_name": "NEW YORK UNIVERSITY",
      "effective_start": "2025-11-13",
      "effective_end": null,
      "justification": "NIH project 5K01DA058408-03"
    },
    {
      "department_name": "BIOMEDICAL ENGINEERING",
      "institution_name": "JOHNS HOPKINS UNIVERSITY",
      "effective_start": "2025-11-13",
      "effective_end": null,
      "justification": "NIH project 5R01CA287422-03"
    },
    {
      "department_name": "ENGINEERING (ALL TYPES)",
      "institution_name": "UNIVERSITY OF CALIFORNIA, SAN DIEGO",
      "effective_start": "2025-11-13",
      "effective_end": null,
      "justification": "NIH project 5R35GM142725-05"
    },
    {
      "department_name": "INTERNAL MEDICINE/MEDICINE",
      "institution_name": "HARVARD MEDICAL SCHOOL",
      "effective_start": "2025-11-13",
      "effective_end": null,
      "justification": "NIH project 5F30CA268631-04"
    },
    {
      "department_name": "PSYCHOLOGY",
      "institution_name": "NORTHEASTERN UNIVERSITY",
      "effective_start": "2025-11-13",
      "effective_end": null,
      "justification": "NIH project 5K23MH132896-02"
    },
    {
      "department_name": "Unknown Department",
      "institution_name": "STANFORD UNIVERSITY",
      "effective_start": "2025-11-13",
      "effective_end": null,
      "justification": "NIH project 5P41EB027060-05"
    },
    {
      "department_name": "BIOCHEMISTRY",
      "institution_name": "COLUMBIA UNIVERSITY HEALTH SCIENCES",
      "effective_start": "2025-11-13",
      "effective_end": null,
      "justification": "NIH project 5R35GM150546-03"
    },
    {
      "department_name": "Unknown Department",
      "institution_name": "CEDARS-SINAI MEDICAL CENTER",
      "effective_start": "2025-11-13",
      "effective_end": null,
      "justification": "NIH project 5R01LM014572-02"
    },
    {
      "department_name": "BIOSTATISTICS & OTHER MATH SCI",
      "institution_name": "FLORIDA INTERNATIONAL UNIVERSITY",
      "effective_start": "2025-11-13",
      "effective_end": null,
      "justification": "NIH project 5R35GM153434-02"
    },
    {
      "department_name": "Unknown Department",
      "institution_name": "COLLABORATIONS PHARMACEUTICALS, INC.",
      "effective_start": "2025-11-13",
      "effective_end": null,
      "justification": "NIH project 5R44ES033855-03"
    },
    {
      "department_name": "PUBLIC HEALTH & PREV MEDICINE",
      "institution_name": "UNIVERSITY OF CALIFORNIA, SAN FRANCISCO",
      "effective_start": "2025-11-13",
      "effective_end": null,
      "justification": "NIH project 5K25AG071840-04"
    },
    {
      "department_name": "Unknown Department",
      "institution_name": "UNIVERSITY OF PITTSBURGH AT PITTSBURGH",
      "effective_start": "2025-11-13",
      "effective_end": null,
      "justification": "NIH project 5P30EY008098-37"
    },
    {
      "department_name": "PSYCHIATRY",
      "institution_name": "WEILL MEDICAL COLL OF CORNELL UNIV",
      "effective_start": "2025-11-13",
      "effective_end": null,
      "justification": "NIH project 1R01OD039830-01"
    },
    {
      "department_name": "NONE",
      "institution_name": "UNIVERSITY OF PENNSYLVANIA",
      "effective_start": "2025-11-13",
      "effective_end": null,
      "justification": "NIH project 5F30MD020264-02"
    },
    {
      "department_name": "CHEMISTRY",
      "institution_name": "NORTHEASTERN UNIVERSITY",
      "effective_start": "2025-11-13",
      "effective_end": null,
      "justification": "NIH project 5U01HG012022-05"
    },
    {
      "department_name": "INTERNAL MEDICINE/MEDICINE",
      "institution_name": "NORTHWESTERN UNIVERSITY AT CHICAGO",
      "effective_start": "2025-11-13",
      "effective_end": null,
      "justification": "NIH project 5K23HL169815-02"
    },
    {
      "department_name": "BIOSTATISTICS & OTHER MATH SCI",
      "institution_name": "UNIVERSITY OF NORTH TEXAS",
      "effective_start": "2025-11-13",
      "effective_end": null,
      "justification": "NIH project 2R35GM133657-07"
    },
    {
      "department_name": "BIOSTATISTICS & OTHER MATH SCI",
      "institution_name": "STANFORD UNIVERSITY",
      "effective_start": "2025-11-13",
      "effective_end": null,
      "justification": "NIH project 1R35GM158122-01"
    },
    {
      "department_name": "BIOMEDICAL ENGINEERING",
      "institution_name": "UNIVERSITY OF WISCONSIN-MADISON",
      "effective_start": "2025-11-13",
      "effective_end": null,
      "justification": "NIH project 5R21EB034411-03"
    },
    {
      "department_name": "CHEMISTRY",
      "institution_name": "STANFORD UNIVERSITY",
      "effective_start": "2025-11-13",
      "effective_end": null,
      "justification": "NIH project 2R01GM140090-05"
    },
    {
      "department_name": "PUBLIC HEALTH & PREV MEDICINE",
      "institution_name": "PENNSYLVANIA STATE UNIV HERSHEY MED CTR",
      "effective_start": "2025-11-13",
      "effective_end": null,
      "justification": "NIH project 5R35GM154888-02"
    },
    {
      "department_name": "CHEMISTRY",
      "institution_name": "UNIVERSITY OF MEMPHIS",
      "effective_start": "2025-11-13",
      "effective_end": null,
      "justification": "NIH project 5R35GM145206-04"
    },
    {
      "department_name": "INTERNAL MEDICINE/MEDICINE",
      "institution_name": "ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI",
      "effective_start": "2025-11-13",
      "effective_end": null,
      "justification": "NIH project 5R01LM013766-04"
    },
    {
      "department_name": "PSYCHIATRY",
      "institution_name": "UNIVERSITY OF PITTSBURGH AT PITTSBURGH",
      "effective_start": "2025-11-13",
      "effective_end": null,
      "justification": "NIH project 5K01MH122741-05"
    },
    {
      "department_name": "INTERNAL MEDICINE/MEDICINE",
      "institution_name": "UNIVERSITY OF PITTSBURGH AT PITTSBURGH",
      "effective_start": "2025-11-13",
      "effective_end": null,
      "justification": "NIH project 5R01DA044985-07"
    },
    {
      "department_name": "Unknown Department",
      "institution_name": "BOSTON CHILDREN'S HOSPITAL",
      "effective_start": "2025-11-13",
      "effective_end": null,
      "justification": "NIH project 5R35GM133725-08"
    },
    {
      "department_name": "PEDIATRICS",
      "institution_name": "UT SOUTHWESTERN MEDICAL CENTER",
      "effective_start": "2025-11-13",
      "effective_end": null,
      "justification": "NIH project 5R01NS133142-03"
    },
    {
      "department_name": "EMERGENCY MEDICINE",
      "institution_name": "UNIVERSITY OF ILLINOIS AT CHICAGO",
      "effective_start": "2025-11-13",
      "effective_end": null,
      "justification": "NIH project 5K23DA055061-04"
    },
    {
      "department_name": "GENETICS",
      "institution_name": "UNIVERSITY OF WISCONSIN-MADISON",
      "effective_start": "2025-11-13",
      "effective_end": null,
      "justification": "NIH project 1R21AI182816-01A1"
    },
    {
      "department_name": "INTERNAL MEDICINE/MEDICINE",
      "institution_name": "UNIV OF NORTH CAROLINA CHAPEL HILL",
      "effective_start": "2025-11-13",
      "effective_end": null,
      "justification": "NIH project 5K23DK131289-03"
    },
    {
      "department_name": "OBSTETRICS & GYNECOLOGY",
      "institution_name": "UNIV OF NORTH CAROLINA CHAPEL HILL",
      "effective_start": "2025-11-13",
      "effective_end": null,
      "justification": "NIH project 5U01TR003629-04"
    },
    {
      "department_name": "Unknown Department",
      "institution_name": "NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC",
      "effective_start": "2025-11-13",
      "effective_end": null,
      "justification": "NIH project 5K23MH129628-04"
    }
  ]
}